Antibodies, Monoclonal

• 

  Subject Areas on Research

  • "Rescue" platelet GP IIb/IIIa inhibitor therapy in percutaneous coronary intervention: bailing out of a sunken ship. 
  • (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. 
  • 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. 
  • 111-In-capromab pendetide imaging using hybrid-γ camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer. 
  • 14-3-3 proteins are part of an abscisic acid-VIVIPAROUS1 (VP1) response complex in the Em promoter and interact with VP1 and EmBP1. 
  • 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. 
  • 4D11: The Second Mouse? 
  • A 57,000-mol-wt protein uniquely present in nonproliferating cells and senescent human fibroblasts. 
  • A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results. 
  • A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. 
  • A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity. 
  • A G-protein beta gamma-subunit-responsive phosphoinositide 3-kinase activity in human platelet cytosol. 
  • A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. 
  • A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. 
  • A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. 
  • A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors. 
  • A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. 
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. 
  • A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. 
  • A blood group-related polymorphism of CD44 abolishes a hyaluronan-binding consensus sequence without preventing hyaluronan binding. 
  • A combination of 5-fluorouracil and membrane-bound antibody inhibits B-cell lymphoma growth in a mouse model system. 
  • A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines. 
  • A combined approach for purging multidrug-resistant leukemic cell lines in bone marrow using a monoclonal antibody and chemotherapy. 
  • A comparative analysis of EGFR-targeting antibodies for gold nanoparticle CT imaging of lung cancer. 
  • A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation. 
  • A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. 
  • A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. 
  • A cortical granule-specific enzyme, B-1,3-glucanase, in sea urchin eggs. 
  • A desensitization protocol for the mAb cetuximab. 
  • A distinct wave of human T cell receptor gamma/delta lymphocytes in the early fetal thymus: evidence for controlled gene rearrangement and cytokine production. 
  • A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. 
  • A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. 
  • A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. 
  • A high endothelial cell-derived chemokine induces rapid, efficient, and subset-selective arrest of rolling T lymphocytes on a reconstituted endothelial substrate. 
  • A human anti-HIV autoantibody enhances EBV transformation and HIV infection. 
  • A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. 
  • A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure. 
  • A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: results from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. 
  • A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. 
  • A monoclonal antibody reactive with a second epitope of the 67,000-dalton human T cell antigen. 
  • A monoclonal antibody specific for the amino terminal sequence of human prorenin identifies a common epitope on renal and amniotic fluid inactive renins. 
  • A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief. 
  • A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. 
  • A murine monoclonal antibody directed against the carboxyl-terminal domain of GRP78 suppresses melanoma growth in mice. 
  • A new ganglioside of the lactotetraose series, GalNAc-3'-isoLM1, detected in human meconium. 
  • A new method for isolating primary mesenchyme cells of the sea urchin embryo. Panning on wheat germ agglutinin-coated dishes. 
  • A non-neutralizing glycoprotein B monoclonal antibody protects against herpes simplex virus disease in mice. 
  • A novel activation pathway for mature thymocytes. Costimulation of CD2 (T,p50) and CD28 (T,p44) induces autocrine interleukin 2/interleukin 2 receptor-mediated cell proliferation. 
  • A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. 
  • A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study. 
  • A novel monoclonal antibody to CD40 prolongs islet allograft survival. 
  • A novel monoclonal antibody to secreted frizzled-related protein 2 inhibits tumor growth. 
  • A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design. 
  • A novel role for HEB downstream or parallel to the pre-TCR signaling pathway during alpha beta thymopoiesis. 
  • A novel role for XIAP in copper homeostasis through regulation of MURR1. 
  • A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE. 
  • A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. 
  • A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. 
  • A nuclear factor-kappaB inhibitor BAY11-7082 inhibits interactions between human endothelial cells, T cells, and monocytes. 
  • A panel of antibodies useful in the cytologic diagnosis of metastatic melanoma. 
  • A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. 
  • A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer. 
  • A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. 
  • A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer. 
  • A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. 
  • A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. 
  • A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. 
  • A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. 
  • A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). 
  • A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. 
  • A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. 
  • A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. 
  • A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. 
  • A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer. 
  • A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. 
  • A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. 
  • A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. 
  • A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. 
  • A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB). 
  • A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin in living-donor kidney transplantation. 
  • A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. 
  • A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. 
  • A rapid troponin I assay is not optimal for determination of troponin status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes. 
  • A rapidly dividing human medulloblastoma cell line (D283 MED) expresses all three neurofilament subunits. 
  • A rat liver 57-kDa protein is identified to share antigenic determinants with statin, a marker for nonproliferating cells. 
  • A reevaluation of CD22 expression in human lung cancer. 
  • A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions. 
  • A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. 
  • A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. 
  • A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. 
  • A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. 
  • A sensitive epitope-blocking ELISA for the detection of Chikungunya virus-specific antibodies in patients. 
  • A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells. 
  • A subgroup of murine monoclonal anti-deoxyribonucleic acid antibodies traverse the cytoplasm and enter the nucleus in a time-and temperature- dependent manner. 
  • A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes. 
  • A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. 
  • A tool for evaluating heterogeneity in avidity of polyclonal antibodies. 
  • A tyrosine kinase physically associates with the beta-subunit of the human IL-2 receptor. 
  • ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). 
  • AD2, a human molecule involved in the interaction of T cells with epidermal keratinocytes and thymic epithelial cells. 
  • ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. 
  • Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing. 
  • Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. 
  • Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study. 
  • Abciximab readministration: results of the ReoPro Readministration Registry. 
  • Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. 
  • Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti-RB antibodies. 
  • Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. 
  • Absence of estrogen receptor in human melanoma as evaluated by a monoclonal antiestrogen receptor antibody. 
  • Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Application to radiolabeling. 
  • Acquired vulvar lymphangioma circumscriptum: a comparison of 12 cases with Crohn's associated lesions or radiation therapy induced tumors. 
  • Actin and myosin function in acanthamoeba. 
  • Activated lymphocytes promote endothelial cell detachment from matrix: a role for modulation of endothelial cell beta 1 integrin affinity. 
  • Activation of T lymphocytes for adhesion and cytokine expression by toxin-conjugated anti-CD3 monoclonal antibodies. 
  • Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. 
  • Active immunotherapy for TNF-mediated inflammation using self-assembled peptide nanofibers. 
  • Acute graft-vs-host disease: pathobiology and management. 
  • Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. 
  • Acute myelogenous leukemia associated with Ollier disease. 
  • Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. 
  • Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. 
  • Acute profound thrombocytopenia after c7E3 Fab therapy. 
  • Adalimumab for the treatment of psoriasis. 
  • Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. 
  • Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. 
  • Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer. 
  • Adenovirus infections in pediatric small bowel transplant recipients. 
  • Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study. 
  • Advanced prostate cancer: the future. 
  • Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41. 
  • Aggregate complexes of HIV-1 induced by multimeric antibodies. 
  • Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. 
  • Alemtuzumab for the prevention and treatment of graft-versus-host disease. 
  • Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. 
  • Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. 
  • Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. 
  • Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation. 
  • Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. 
  • Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. 
  • Alemtuzumab. 
  • Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. 
  • Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. 
  • Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia. 
  • Alopecia in IL-10-deficient mouse pups is c-kit-dependent and can be triggered by iron deficiency. 
  • Alpha-glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro. 
  • Altered expression of ganglioside phenotypes of human gliomas in vivo and in vitro. 
  • Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. 
  • Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials. 
  • Amplification of suppressor inducer pathway with monoclonal antibody, anti-2H4, identifying a novel epitope of the common leukocyte antigen/T200 antigen. 
  • An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1. 
  • An Atlas of Genetic Variation Linking Pathogen-Induced Cellular Traits to Human Disease. 
  • An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. 
  • An antibody to human thymic Hassall's body epithelium recognizes a subset of blood group A antigens. 
  • An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab. 
  • An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation. 
  • An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies. 
  • An evidence-based review of CGRP mechanisms in the propagation of chronic visceral pain. 
  • An in vitro neurite-promoting antigen functions in axonal regeneration in vivo. 
  • An intermediate filament-associated protein, p50, recognized by monoclonal antibodies. 
  • An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors. 
  • An overview of the results of the EPIC trial. 
  • Analysis of Fc gamma receptors on human peripheral blood leukocytes by flow microfluorometry. I. Receptor distributions on monocytes, T gamma cells and cells labeled with the 3Al anti-T cell monoclonal antibody. 
  • Analysis of T-cell differentiation antigens in acute lymphatic leukemia using monoclonal antibodies. 
  • Analysis of T-cell subsets in B-cell chronic lymphocytic leukemia: a correlation with the stage of disease. 
  • Analysis of complex matrices functional in neuronal process extension using monoclonal antibodies in vitro and in vivo. 
  • Analysis of corneal and conjunctival microenvironments using monoclonal antibodies. 
  • Analysis of expression of CD2, CD3, and T cell antigen receptor molecules during early human fetal thymic development. 
  • Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. 
  • Analysis of multi-arm tumor growth trials in xenograft animals using phase change adaptive piecewise quadratic models. 
  • Analysis of the T-cell receptor beta-chain variable-region (V beta) repertoire in monozygotic twins discordant for human immunodeficiency virus: evidence for perturbations of specific V beta segments in CD4+ T cells of the virus-positive twins. 
  • Analysis of the globose basal cell compartment in rat olfactory epithelium using GBC-1, a new monoclonal antibody against globose basal cells. 
  • Analysis of the role of membrane polarity in polycystic kidney disease of transgenic SBM mice. 
  • Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. 
  • Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions. 
  • Angiostatin-like activity of a monoclonal antibody to the catalytic subunit of F1F0 ATP synthase. 
  • Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. 
  • Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. 
  • Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. 
  • Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. 
  • Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. 
  • Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. 
  • Anti-Ebola MAb 17A3 reacts with bovine and human alpha-2-macroglobulin proteins. 
  • Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. 
  • Anti-GM2 monoclonal antibodies induce necrosis in GM2-rich cultures of a human glioma cell line. 
  • Anti-U1A monoclonal antibodies recognize unique epitope targets of U1A which are involved in the binding of U1 RNA. 
  • Anti-angiogenic therapy in renal cell cancer. 
  • Anti-bombesin monoclonal antibodies modulate fetal mouse lung growth and maturation in utero and in organ cultures. 
  • Anti-epidermal growth factor receptor therapy for glioblastoma in adults. 
  • Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cells. 
  • Anti-idiotypic monoclonal Ig specific for an anti-laminin Ig heavy chain transgene variable region. 
  • Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. 
  • Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models. 
  • Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis. 
  • Antiadhesive properties of a quaternary structure-specific hybridoma antibody against type 1 fimbriae of Escherichia coli. 
  • Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. 
  • Antibodies as specific renin inhibitors: studies with polyclonal and monoclonal antibodies and Fab fragments. 
  • Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. 
  • Antibodies reactive with class II antigens encoded for by the major histocompatibility complex inhibit human B cell activation. 
  • Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. 
  • Antibodies to DNA. A perspective. 
  • Antibody binding to a conformation-dependent epitope induces L-selectin association with the detergent-resistant cytoskeleton. 
  • Antibody inhibitors of nonmuscle myosin function and assembly. 
  • Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. 
  • Antibody polyspecificity and neutralization of HIV-1: a hypothesis. 
  • Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development? 
  • Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. 
  • Antibody responses to the HIV-1 envelope high mannose patch. 
  • Antibody to E- and L-selectin does not prevent lung injury or mortality in septic baboons. 
  • Antibody to intercellular adhesion molecule 1 (CD54) decreases survival and not lung injury in baboons with sepsis. 
  • Antibody valence and induced signal transduction: the role of antibody valence in anti-CD3-induced signal transduction in isolated normal T cells. 
  • Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. 
  • Antibody-based biosensor for breast cancer with ultrasonic regeneration. 
  • Antibody-dependent enhancement of SIV infection: further characterization and cross reactivity between macaque and sooty mangabey isolates. 
  • Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. 
  • Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling. 
  • Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. 
  • Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. 
  • Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). 
  • Anticancer antibodies for lung cancer. 
  • Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance. 
  • Antigenic heterogeneity of human anaplastic gliomas and glioma-derived cell lines defined by monoclonal antibodies. 
  • Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. 
  • Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. 
  • Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. 
  • Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, nontoxic, highly efficient transfection method. 
  • Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. 
  • Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. 
  • Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. 
  • Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Antithrombotic therapy in patients undergoing coronary angioplasty. 
  • Antithymocyte globulin stimulates human hematopoietic progenitor cells. 
  • Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. 
  • Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. 
  • Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. 
  • Application of a panel of antiganglioside monoclonal antibodies to cytologic specimens. 
  • Application of a unique monoclonal antibody as a marker for nonproliferating subpopulations of cells of some tissue. 
  • Application of an antibody biochip for p53 detection and cancer diagnosis. 
  • Applications of 211At and 223Ra in targeted alpha-particle radiotherapy. 
  • Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors. 
  • Are autoantibodies the targets of B-cell-directed therapy? 
  • Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis. 
  • Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. 
  • Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas. 
  • Assembly of a chemically synthesized peptide of Escherichia coli type 1 fimbriae into fimbria-like antigenic structures. 
  • Assessing the value of newer pharmacologic agents in non-ST elevation patients: a decision support system application. 
  • Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. 
  • Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). 
  • Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. 
  • Association of anemia and physical disability among patients with rheumatoid arthritis. 
  • Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. 
  • Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. 
  • Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS. 
  • Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. 
  • Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. 
  • Astrocyte cytolysis by MHC class II-specific mouse T cell clones. 
  • Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. 
  • Attrition of memory CD8 T cells during sepsis requires LFA-1. 
  • Augmentation of tumor-specific immunity by upregulation of apoptotic melanoma cell calreticulin expression. 
  • Autocrine growth factors and neuroendocrine markers in the development of small-cell lung cancer. 
  • Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. 
  • Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. 
  • Avastin: more questions than answers. . 
  • Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. 
  • Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. 
  • B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. 
  • B cell depletion reduces the development of atherosclerosis in mice. 
  • B cell-ablative therapy for the treatment of autoimmune diseases. 
  • B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. 
  • B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. 
  • B lymphocytes differentially influence acute and chronic allograft rejection in mice. 
  • B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. 
  • B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. 
  • B-lymphocyte contributions to human autoimmune disease. 
  • B-lymphocyte depletion ameliorates Sjögren's syndrome in Id3 knockout mice. 
  • B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. 
  • BAFF is increased in renal transplant patients following treatment with alemtuzumab. 
  • BRCA2 monoclonal antibodies react with differentiating epithelium. 
  • BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells. 
  • Bacterial contamination of needles used for intravitreal injections: a prospective, multicenter study. 
  • Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies. 
  • Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. 
  • Basiliximab decreases the incidence of acute rejection after intestinal transplantation. 
  • Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy. 
  • Benefit of angiographic spontaneous reperfusion in STEMI: does it extend to diabetic patients? 
  • Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. 
  • Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. 
  • Bevacizumab and everolimus in renal cancer: a rational way forward. 
  • Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. 
  • Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data. 
  • Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. 
  • Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration. 
  • Bevacizumab for patients with metastatic renal cancer: an update. 
  • Bevacizumab for retinopathy of prematurity. 
  • Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. 
  • Bevacizumab in colorectal cancer. 
  • Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. 
  • Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. 
  • Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. 
  • Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. 
  • Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. 
  • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. 
  • Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. 
  • Bilateral panocular involvement with mantle-cell lymphoma. 
  • Binding of factor VIII inhibitors to discrete regions of the factor VIII C2 domain disrupt phospholipid binding. 
  • Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. 
  • Binding specificity of a monoclonal anti-DNA antibody. 
  • Biochemical characterization of antibodies submitted as reactive with glycophorin species. 
  • Biochemical identity and characterization of the mouse interleukin-2 receptor beta and gamma c subunits. 
  • Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. 
  • Biolayer interferometry predicts ELISA performance of monoclonal antibody pairs for Plasmodium falciparum histidine-rich protein 2. 
  • Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. 
  • Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer. 
  • Biologics in organ transplantation. 
  • Biologics in relapsing polychondritis: a literature review. 
  • Biosynthesis of EGF receptor, transferrin receptor and colligin by cultured human keratinocytes and the effect of retinoic acid. 
  • Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. 
  • Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS. 
  • Blockade of L-selectin attenuates reperfusion injury in a rat model. 
  • Blockade of T- and B-lymphocyte development by antibody to the gamma c subunit of the receptors for interleukins 2, 4, and 7. 
  • Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. 
  • Blocking CCR7 at the ocular surface impairs the pathogenic contribution of dendritic cells in allergic conjunctivitis. 
  • Blocking L-selectin function attenuates reperfusion injury following hemorrhagic shock in rabbits. 
  • Bombesin increases fetal lung growth and maturation in utero and in organ culture. 
  • Bombesin-like peptide mediates lung injury in a baboon model of bronchopulmonary dysplasia. 
  • Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. 
  • Brain tumors in man and animals: report of a workshop. 
  • Brain-derived neurotrophic factor but not vesicular zinc promotes TrkB activation within mossy fibers of mouse hippocampus in vivo. 
  • Branhamella catarrhalis activates human B lymphocytes following interactions with surface IgD and class I major histocompatibility complex antigens. 
  • Breast cancer. Clinical practice guidelines in oncology. 
  • Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. 
  • Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. 
  • Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. 
  • Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. 
  • Broadly neutralizing monoclonal antibodies for HIV prevention. 
  • Bronchiolitis. 
  • Burosumab for the Treatment of Tumor-Induced Osteomalacia. 
  • Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. 
  • C-terminal region of human T cell lymphotropic virus type I (HTLVI) p19 core protein is immunogenic in humans and contains an HTLVI-specific epitope. 
  • C-terminal repeat domain kinase I phosphorylates Ser2 and Ser5 of RNA polymerase II C-terminal domain repeats. 
  • CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study. 
  • CD antigens 1993. 
  • CD1 expression by dendritic cells in human leprosy lesions: correlation with effective host immunity. 
  • CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. 
  • CD14-dependent mechanism for endotoxin-mediated nitric oxide synthesis in murine macrophages. 
  • CD19 amplification of B lymphocyte Ca2+ responses: a role for Lyn sequestration in extinguishing negative regulation. 
  • CD19: a promising B cell target for rheumatoid arthritis. 
  • CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. 
  • CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. 
  • CD30-activation-mediated growth inhibition of anaplastic large-cell lymphoma cell lines: apoptosis or cell-cycle arrest? 
  • CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. 
  • CD4+ T-cell and monocyte interdependence during discordant xenoimmune responses. 
  • CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model. 
  • CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. 
  • CD44 antibody against In(Lu)-related p80, lymphocyte-homing receptor molecule inhibits the binding of human erythrocytes to T cells. 
  • CD45 mAb induces cell adhesion in peripheral blood mononuclear cells via lymphocyte function-associated antigen-1 (LFA-1) and intercellular cell adhesion molecule 1 (ICAM-1). 
  • CD7 and CD28 are required for murine CD4+CD25+ regulatory T cell homeostasis and prevention of thyroiditis. 
  • CD83 expression is a sensitive marker of activation required for B cell and CD4+ T cell longevity in vivo. 
  • CD9 plays a role in Schwann cell migration in vitro. 
  • CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. 
  • CFTR: development of high- affinity antibodies and localization in sweat gland. 
  • COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. 
  • CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. 
  • CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. 
  • CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8. 
  • CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin. 
  • Cadaveric renal transplantation in the cyclosporine and OKT3 eras: an update of the University of Wisconsin-Madison experience. 
  • Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. 
  • Campath-1H in intestinal and multivisceral transplantation: preliminary data. 
  • Campath-1H in renal transplantation: The University of Wisconsin experience. 
  • Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. 
  • Campath-1H use in pediatric renal transplantation. 
  • Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. 
  • Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. 
  • Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award. 
  • Candidate counterparts of Sézary cells and adult T-cell lymphoma-leukaemia cells in normal peripheral blood: an ultrastructural study with the immunogold method and monoclonal antibodies. 
  • Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity. 
  • Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. 
  • Capromab Pendetide imaging of prostate cancer. 
  • Carbohydrate Microarrays Identify Blood Group Precursor Cryptic Epitopes as Potential Immunological Targets of Breast Cancer. 
  • Carbohydrate changes in pre- and peri-implantation mouse embryos as detected by a monoclonal antibody. 
  • Carcinoma of the pancreas. Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody. 
  • Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction". 
  • Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. 
  • Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. 
  • Cartilage-binding antibodies induce pain through immune complex-mediated activation of neurons. 
  • Case reports of heart failure after therapy with a tumor necrosis factor antagonist. 
  • Catabolism of radioiodinated murine monoclonal antibody F(ab')2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods. 
  • Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. 
  • Cdc2 phosphorylation of nucleolin demarcates mitotic stages and Alzheimer's disease pathology. 
  • Cell binding and tumor inhibiting functions of a new antihuman melanoma murine monoclonal antibody. 
  • Cell polarity in sea urchin embryos: reorientation of cells occurs quickly in aggregates. 
  • Cell signaling modifiers in prostate cancer. 
  • Cell surface GRP78 signaling: An emerging role as a transcriptional modulator in cancer. 
  • Cell surface expression of major histocompatibility class I antigens is modulated by P-glycoprotein transporter. 
  • Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides. 
  • Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals. 
  • Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. 
  • Central tolerance regulates B cells reactive with Goodpasture antigen alpha3(IV)NC1 collagen. 
  • Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). 
  • Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. 
  • Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. 
  • Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. 
  • Challenges in the pursuit of immune tolerance. 
  • Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. 
  • Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. 
  • Characterization and idiotypic analysis of an anti-RNP monoclonal antibody. 
  • Characterization of 57 kDa statin as a true marker for growth arrest in tissue by its disappearance from regenerating liver. 
  • Characterization of B-cell type chronic lymphocytic leukemia cells by surface markers and a monoclonal antibody. 
  • Characterization of Casirivimab Plus Imdevimab, Sotrovimab, and Bamlanivimab Plus Etesevimab-Derived Interference in Serum Protein Electrophoresis and Immunofixation Electrophoresis. 
  • Characterization of T lymphocyte and monocyte populations in HLA B8/DRw3 normal individuals and in patients with dermatitis herpetiformis. 
  • Characterization of a B lymphoblastoid cell line mutant that secretes HLA-A2. 
  • Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop. 
  • Characterization of a monoclonal antibody (5E9) that defines a human cell surface antigen of cell activation. 
  • Characterization of a monoclonal antibody specific for human active renin. 
  • Characterization of a monoclonal antibody, RTE-21, that binds to keratohyalin granule-associated proteins in epithelial cells of human skin and thymus. 
  • Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. 
  • Characterization of a novel family of ciliary body glycoproteins. 
  • Characterization of a novel human corneal endothelial antigen. 
  • Characterization of circulating and cutaneous IgA immune complexes in patients with dermatitis herpetiformis. 
  • Characterization of microtubule-associated protein MAP1B: phosphorylation state, light chains, and binding to microtubules. 
  • Characterization of monoclonal antibodies to Acanthamoeba myosin-I that cross-react with both myosin-II and low molecular mass nuclear proteins. 
  • Characterization of monoclonal antibodies with specificity for DNA and the synthetic polypeptide antigen (T,G)-A-L. 
  • Characterization of prostate-tissue-directed monoclonal antibody, alpha-Pro 13. 
  • Characterization of renal neoplasms with monoclonal antibodies to leukocyte differentiation antigens. 
  • Characterization of the binding epitope of the monoclonal antibody DMAb-1 to ganglioside GM2. 
  • Characterization of the plasminogen receptors of normal and rheumatoid arthritis human synovial fibroblasts. 
  • Characterization of the serum In(Lu)-related antigen: identification of a serum protein related to erythrocyte p80. 
  • Characterization of the surface topography and putative tertiary structure of the human CD7 molecule. 
  • Characterization of the tissue regression process in the uterus of older mice as apoptotic by the presence of Tp30, an isoform of terminin. 
  • Characterization of three restricted specificity monoclonal antibodies raised against the human glioma cell line D-54 MG. 
  • Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. 
  • Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. 
  • Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. 
  • Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. 
  • Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent. 
  • Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. 
  • Cholinergic innervation of the superior colliculus in the cat. 
  • Chromosome mapping of human cell surface molecules: monoclonal anti-human lymphocyte antibodies 4F2, A3D8, and A1G3 define antigens controlled by different regions of chromosome 11. 
  • Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. 
  • Circulating glycoconjugates in CSF of meningioma patients. 
  • Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. 
  • Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). 
  • Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin. 
  • Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. 
  • Clinical applications of a peptide-based vaccine for glioblastoma. 
  • Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. 
  • Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. 
  • Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials. 
  • Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. 
  • Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. 
  • Clinical immunotherapy for brain tumors. 
  • Clinical isolates of measles virus use CD46 as a cellular receptor. 
  • Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. 
  • Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. 
  • Clinical utility of serial and continuous ST-segment recovery assessment in patients with acute ST-elevation myocardial infarction: assessing the dynamics of epicardial and myocardial reperfusion. 
  • Clinicopathologic aspects of E rosette negative T cell acute lymphocytic leukemia: a Pediatric Oncology Group study. 
  • Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer. 
  • Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: location of lysine residues and implications for radiolabeling. 
  • Clusterin promotes the aggregation and adhesion of renal porcine epithelial cells. 
  • Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. 
  • Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1. 
  • Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. 
  • Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. 
  • Combination anti-CD2 and anti-CD3 monoclonal antibodies induce tolerance while altering interleukin-2, interleukin-4, tumor necrosis factor, and transforming growth factor-beta production. 
  • Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. 
  • Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. 
  • Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. 
  • Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. 
  • Combination therapy with anti-HIV-1 antibodies maintains viral suppression. 
  • Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. 
  • Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. 
  • Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. 
  • Combined chemoseparation and immunoseparation of clonogenic T lymphoma cells from human bone marrow using 2'-deoxycoformycin, deoxyadenosine, 3A1 monoclonal antibody, and complement. 
  • Combined modality treatment for rectal cancer. 
  • Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. 
  • Combined-modality therapy for rectal cancer: future prospects. 
  • Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. 
  • Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial). 
  • Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model. 
  • Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts. 
  • Comparative tissue distribution in mice of the alpha-emitter 211At and 131I as labels of a monoclonal antibody and F(ab')2 fragment. 
  • Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. 
  • Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. 
  • Comparison of PSGL-1 microbead and neutrophil rolling: microvillus elongation stabilizes P-selectin bond clusters. 
  • Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). 
  • Comparison of angioplasty with stenting in acute myocardial infarction. 
  • Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. 
  • Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy). 
  • Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. 
  • Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. 
  • Comparison of in vivo efficacy and mechanism of action of antimurine monoclonal antibodies directed against TCR alpha beta (H57-597) and CD3 (145-2C11). 
  • Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. 
  • Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration. 
  • Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma. 
  • Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study). 
  • Comparison of various methods for delivering radiolabeled monoclonal antibody to normal rat brain. 
  • Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. 
  • Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer. 
  • Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. 
  • Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. 
  • Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. 
  • Comprehensive analysis of commercially available mouse antichicken monoclonal antibodies for cross-reactivity with peripheral blood leukocytes from commercial turkeys. 
  • Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies. 
  • Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. 
  • Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope. 
  • Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5. 
  • Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. 
  • Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. 
  • Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. 
  • Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs. 
  • Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. 
  • Conservation of the D-mannose-adhesion protein among type 1 fimbriated members of the family Enterobacteriaceae. 
  • Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody. 
  • Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. 
  • Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F. 
  • Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. 
  • Contractile proteins in Drosophila development. 
  • Control of idiotope expression by monoclonal anti-idiotope and idiotope-bearing antibody. 
  • Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. 
  • Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. 
  • Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin. 
  • Coordinator's report--section 2D3. 
  • Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. 
  • Correlation of expression of bombesin-like peptides and receptors with growth inhibition by an anti-bombesin antibody in small-cell lung cancer cell lines. 
  • Correspondence re: Geradts J, Wilentz RE, Roberts H. Immunohistochemical detection of the alternate ink4a-encoded tumor suppressor protein p14(arf) in archival human cancers and cell lines using commercial antibodies: correlation with p16(ink4a) expression. Mod pathol 2001;14:1162-68. 
  • Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models. 
  • Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. 
  • Corticosteroids regulate epithelial cell differentiation and Hassall body formation in the human thymus. 
  • Cost effectiveness of abciximab during routine medical practice. 
  • Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer. 
  • Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial. 
  • Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. 
  • Costimulation blockade: towards clinical application. 
  • Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. 
  • Crizotinib and erlotinib inhibits growth of c-Met+/EGFRvIII+ primary human glioblastoma xenografts. 
  • Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. 
  • Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions. 
  • Cross-Reactive Dengue Virus Antibodies Augment Zika Virus Infection of Human Placental Macrophages. 
  • Cross-Reactivity to Kynureninase Tolerizes B Cells That Express the HIV-1 Broadly Neutralizing Antibody 2F5. 
  • Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. 
  • Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. 
  • Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. 
  • Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. 
  • Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. 
  • Cross-reactivity of a Histoplasma capsulatum antigen enzyme immunoassay in urine specimens from persons with emergomycosis in South Africa. 
  • Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region. 
  • Cultured motor neurons possess calcium-permeable AMPA/kainate receptors. 
  • Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease. 
  • Current status of cardiac surgery in the abciximab-treated patient. 
  • Current status of therapy of solid tumors: brain tumor therapy. 
  • Cutaneous T cell lymphoma. Lymphocyte phenotype analysis after anti-thymocyte globulin therapy. 
  • Cyclophosphamide treatment used to manipulate the immune response for the production of monoclonal antibodies. 
  • Cyclosporine for Dry Eye Associated With Nivolumab: A Case Progressing to Corneal Perforation. 
  • Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation. 
  • Cytochemistry of sex steroid receptors: a critique. 
  • Cytochrome P450IA1 induction and localization in endothelium of vertebrate (teleost) heart. 
  • Cytomegalovirus keratitis after penetrating keratoplasty. 
  • Cytoplasmic inclusion bodies are detected by synthetic antibody in ciliated bronchial epithelium during acute Kawasaki disease. 
  • Cytoplasmic myosin from Drosophila melanogaster. 
  • Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. 
  • Cytotoxic T-lymphocyte-associated antigen-4. 
  • Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia. 
  • D-dimer antigen: current concepts and future prospects. 
  • D6.1, a murine antimelanoma monoclonal antibody from congenitally athymic nude mice immunized with purified melanoma tumor-associated antigen. 
  • D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. 
  • DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. 
  • Daratumumab Use Prior to Kidney Transplant and T Cell-Mediated Rejection: A Case Report. 
  • Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use. 
  • De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer. 
  • Decreased expression of nicotinamide phosphoribosyltransferase in patients with juvenile idiopathic arthritis receiving methotrexate. 
  • Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. 
  • Defining best supportive care. 
  • Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis. 
  • Deletion of V335 from the L2 domain of the insulin receptor results in a conformationally abnormal receptor that is unable to bind insulin and causes Donohue's syndrome in a human subject. 
  • Demonstration of abnormalities in expression of thymic epithelial surface antigens in severe cellular immunodeficiency diseases. 
  • Demonstration of abnormalities in expression of thymic epithelial surface antigens in severe cellular immunodeficiency diseases. 
  • Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies. 
  • Demonstration of phenotypic abnormalities of thymic epithelium in thymoma including two cases with abundant Langerhans cells. 
  • Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants. 
  • Dendritic cells cultured in anti-CD40 antibody-immobilized plates elicit a highly efficient peptide-specific T-cell response. 
  • Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. 
  • Description of monoclonal antibody defining an HLA allotypic determinant that includes specificities within the B5 cross-reacting group. 
  • Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial. 
  • Design, expression, and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration. 
  • Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor. 
  • Detection of acrolein-derived cyclic DNA adducts in human cells by monoclonal antibodies. 
  • Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma. 
  • Detection of antigen in bronchial epithelium and macrophages in acute Kawasaki disease by use of synthetic antibody. 
  • Detection of cross-reactive idiotypes in the serum of patients with bullous pemphigoid. 
  • Detection of early-stage pancreatic adenocarcinoma. 
  • Detection of glioma-associated gangliosides GM2, GD2, GD3, 3'-isoLM1 3',6'-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies. 
  • Detection of minimal residual T cell acute lymphoblastic leukemia by flow cytometry. 
  • Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. 
  • Determination of neutralization activities by a new versatile assay using an HIV-1 genome carrying the Gaussia luciferase gene. 
  • Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. 
  • Determination of proliferation index in advanced ovarian cancer using quantitative image analysis. 
  • Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. 
  • Development and characterization of a monoclonal antibody to human embryonal carcinoma. 
  • Development and distribution of a human B cell subpopulation identified by the HB-4 monoclonal antibody. 
  • Development and validation of a cell-based fluorescent method for measuring antibody affinity. 
  • Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody. 
  • Development of a monoclonal antibody specific for serotype 3 rotavirus strains. 
  • Development, reliability, and validity of a new Preference and Satisfaction Questionnaire. 
  • Developmental regulation of lymphocyte-specific protein 1 (LSP1) expression in thymus during human T-cell maturation. 
  • Diagnosing acute myocardial infarction in patients with left bundle branch block. 
  • Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. 
  • Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment. 
  • Differences in intraepithelial lymphocyte T cell subsets isolated from murine small versus large intestine. 
  • Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate. 
  • Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7 : Differential activities of Nav1.7-targeting monoclonal antibodies. 
  • Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. 
  • Differential effects of donor-specific alloantibody. 
  • Differential effects of triamcinolone and bevacizumab in central retinal vein occlusion. 
  • Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production. 
  • Differentiation of human T cells. 
  • Differentiation of human T lymphocytes. I. Acquisition of a novel human cell surface protein (p80) during normal intrathymic T cell maturation. 
  • Difficulties in applying clinical trial information to the practice setting: case of a high-cost drug. 
  • Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing. 
  • Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. 
  • Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. 
  • Direct in vivo measurement of targeted binding in a human tumor xenograft. 
  • Direct localization of monoclonal antibody-binding sites on Acanthamoeba myosin-II and inhibition of filament formation by antibodies that bind to specific sites on the myosin-II tail. 
  • Discontinuous expression of a membrane antigen (HB-7) during B lymphocyte differentiation. 
  • Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. 
  • Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas. 
  • Disruption of intrathymic CD4-Ia interactions on immature CD4+CD8+ thymocytes results in diminished TCR expression on mature CD8+ T cell progeny. 
  • Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. 
  • Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4. 
  • Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. 
  • Distribution and physical properties of BCA200, a Mr 200,000 glycoprotein selectively associated with human breast cancer. 
  • Distribution of CD44 variant isoforms in human skin: differential expression in components of benign and malignant epithelia. 
  • Distribution of type VI collagen in human gliomas: comparison with fibronectin and glioma-mesenchymal matrix glycoprotein. 
  • Diverse endogenous light chains contribute to basement membrane reactivity in nonautoimmune mice transgenic for an anti-laminin Ig heavy chain. 
  • Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. 
  • Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. 
  • Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? 
  • Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. 
  • Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial. 
  • Donor-reactive T-cell stimulation history and precursor frequency: barriers to tolerance induction. 
  • Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. 
  • Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. 
  • Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. 
  • Dosing and administration of ReoPro (c7E3 Fab). 
  • Double antibody radioimmunoassay for monitoring metastatic breast cancer. 
  • Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. 
  • Dr(a-) polymorphism of decay accelerating factor. Biochemical, functional, and molecular characterization and production of allele-specific transfectants. 
  • Drosophilia spectrin. I. Characterization of the purified protein. 
  • Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer. 
  • Dual targeting: Combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients. 
  • Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply. 
  • Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. 
  • Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. 
  • Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. 
  • Dynamic actin polymerization drives T cell receptor-induced spreading: a role for the signal transduction adaptor LAT. 
  • Dynamic antibody-binding properties in the pathogenesis of HIT. 
  • E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. 
  • EGF mutant receptor vIII as a molecular target in cancer therapy. 
  • EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. 
  • EGFRvIII as a promising target for antibody-based brain tumor therapy. 
  • ELISA for quantitation of L-selectin shed from leukocytes in vivo. 
  • ESPRIT in context: pharmacology matters! 
  • Early Monoclonal Antibody Administration Can Reduce Both Hospitalizations and Mortality in High-Risk Outpatients With Coronavirus Disease 2019 (COVID-19). 
  • Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. 
  • Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. 
  • Early human T cell development: analysis of the human thymus at the time of initial entry of hematopoietic stem cells into the fetal thymic microenvironment. 
  • Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction. 
  • Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. 
  • Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. 
  • Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data. 
  • Ectoderm cell--ECM interaction is essential for sea urchin embryo skeletogenesis. 
  • Editorial: Infections of the immunocompromised host: a musing on the changing times. 
  • Editorial: Licensing and Use of New Therapies in MS: Where Are We Going? 
  • Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. 
  • Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host. 
  • Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. 
  • Effect of Steel factor and leukaemia inhibitory factor on murine primordial germ cells in culture. 
  • Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). 
  • Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. 
  • Effect of an anti-C5a monoclonal antibody indicates a prominent role for anaphylatoxin in pulmonary xenograft dysfunction. 
  • Effect of anti-CD4 antibody treatment on inflammatory arthritis in MRL-lpr/lpr mice. 
  • Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission. 
  • Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. 
  • Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. 
  • Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. 
  • Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time. 
  • Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview. 
  • Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. 
  • Effect of radioiodination on the binding of monoclonal antibody DF3 to breast carcinoma cells. 
  • Effective antibody therapy in herpes simplex virus ocular infection. Characterization of recipient immune response. 
  • Effectiveness and safety of abciximab after failed thrombolytic therapy. 
  • Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. 
  • Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. 
  • Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. 
  • Effects of TNF-alpha on expression of ICAM-1 in human airway epithelial cells in vitro. Signaling pathways controlling surface and gene expression. 
  • Effects of anti-CD18 monoclonal antibody, R15.7, on the cardiopulmonary manifestations of group B streptococcal sepsis in piglets. 
  • Effects of combined treatment with CD25- and CD154-specific monoclonal antibodies in non-human primate allotransplantation. 
  • Effects of dose and duration of anti-CD154 antibody therapy in preventing renal allograft rejection in a nonhuman primate model. 
  • Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. 
  • Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. 
  • Effects of topical glaucoma drugs on fistulized rabbit conjunctiva. 
  • Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. 
  • Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. 
  • Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. 
  • Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. 
  • Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. 
  • Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. 
  • Efficacy and safety of minimal dose (< or =1,000 units) unfractionated heparin with abciximab in percutaneous coronary intervention. 
  • Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. 
  • Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. 
  • Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. 
  • Efficacy of abciximab readministration in coronary intervention. 
  • Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. 
  • Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis. 
  • Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. 
  • Efficacy of immune therapy in early experimental Naegleria fowleri meningitis. 
  • Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. 
  • Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. 
  • Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. 
  • Electron microscopic identification of exposed plasmin epitopes in alpha 2-macroglobulin-plasmin complex using monoclonal antibody-colloidal gold adducts. 
  • Elimination of clonogenic malignant human T cells using monoclonal antibodies in combination with 2'-deoxycoformycin. 
  • Elimination of mycoplasma from human B-lymphoblastoid cell lines. 
  • Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. 
  • Embolic protection and platelet inhibition during renal artery stenting. 
  • Embryo dissociation, cell isolation, and cell reassociation. 
  • Embryonic cellular organization: differential restriction of fates as revealed by cell aggregates and lineage markers. 
  • Embryonic chick cartilage produces its own somatomedin-like peptide to stimulate cartilage growth in vitro. 
  • Emerging therapeutic approaches in the management of retinal angiogenesis and edema. 
  • Emerging therapeutics for ocular surface disease. 
  • Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors. 
  • Emerging treatments for ulcerative colitis: a systematic review. 
  • En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase. 
  • Endothelial metaplasia in the iridocorneal endothelial syndrome. 
  • Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. 
  • Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. 
  • Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation. 
  • Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia. 
  • Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade. 
  • Enhanced integrative repair of the porcine meniscus in vitro by inhibition of interleukin-1 or tumor necrosis factor alpha. 
  • Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate. 
  • Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: Application of the thermal equivalency equation. 
  • Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia. 
  • Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. 
  • Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents. 
  • Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. 
  • Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. 
  • EpCAM: A new therapeutic target for an old cancer antigen. 
  • Epidemiology of respiratory syncytial virus in various regions within North Carolina during multiple seasons. 
  • Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. 
  • Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. 
  • Epidermal growth factor receptor-targeted therapy for pancreatic cancer. 
  • Epithelial-thymocyte interactions in human thymus. 
  • Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. 
  • Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin. 
  • Epitope-specific signaling through CD45 on T lymphocytes leads to cAMP synthesis in monocytes after ICAM-1-dependent cellular interaction. 
  • Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system. 
  • Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. 
  • Establishment of the DU.528 human lymphohemopoietic stem cell line. 
  • Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. 
  • Estimating the probability of polyreactive antibodies 4E10 and 2F5 disabling a gp41 trimer after T cell-HIV adhesion. 
  • Estrogen receptor determination by monoclonal antibody in fine needle aspiration breast cancer cytologies: a marker of hormone response. 
  • Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. 
  • Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK. 
  • Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent. 
  • Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. 
  • Evaluation of hypertension as a marker of bevacizumab efficacy. 
  • Evaluation of lymphocyte differentiation in primary and secondary immunodeficiency diseases. 
  • Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2. 
  • Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. 
  • Evidence for a novel hybrid immunotoxin recognizing ricin A-chain by one antigen-combining site and a prostate-restricted antigen by the remaining antigen-combining site: potential for immunotherapy. 
  • Evidence for the Role of a Second Fc-Binding Receptor in Placental IgG Transfer in Nonhuman Primates. 
  • Evidence that CDw108 membrane protein bears the JMH blood group antigen. 
  • Evidence that several high-frequency human blood group antigens reside on phosphatidylinositol-linked erythrocyte membrane proteins. 
  • Evidence that the platinum-reactive methionyl residue of the alpha 2-macroglobulin receptor recognition site is not in the carboxyl-terminal receptor binding domain. 
  • Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. 
  • Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. 
  • Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. 
  • Exploring Glycan Markers for Immunotyping and Precision-targeting of Breast Circulating Tumor Cells. 
  • Exploring the basis of peptide-carbohydrate crossreactivity: evidence for discrimination by peptides between closely related anti-carbohydrate antibodies. 
  • Expression and function of the gamma c subunit of the IL-2, IL-4, and IL-7 receptors. Distinct interaction of gamma c in the IL-4 receptor. 
  • Expression and functional characterization of chimeras between human and bovine vitamin-K-dependent protein-S-defining modules important for the species specificity of the activated protein C cofactor activity. 
  • Expression and production of interleukin-10 by human trophoblast: relationship to pregnancy immunotolerance. 
  • Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody. 
  • Expression of CD44 molecules and CD44 ligands during human thymic fetal development: expression of CD44 isoforms is developmentally regulated. 
  • Expression of O6-alkylguanine-DNA alkyltransferase in Mer+ and Mer- human cell extracts probed with specific monoclonal antibodies. 
  • Expression of T-lymphoblast-encoded HLA-DR antigens on human T-B lymphoblast hybrids. 
  • Expression of T-lymphoblast-encoded HLA-DR, MT, and SB antigens on human T-B lymphoblast hybrids. 
  • Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. 
  • Expression of a highly conserved anti-DNA idiotype in normal and autoimmune mice. 
  • Expression of a melanoma-tumor-associated antigen as demonstrated by a monoclonal antibody (D6.1) in cytopathologic preparations of human tumor cells from effusions and needle aspirates. 
  • Expression of a murine cytomegalovirus early-late protein in "latently" infected mice. 
  • Expression of amphiphysin I, an autoantigen of paraneoplastic neurological syndromes, in breast cancer. 
  • Expression of antigens by cultured epithelial cells: comparison of epidermis and thymic epithelium. 
  • Expression of class I histocompatibility antigens on human T-B lymphoblast hybrids. 
  • Expression of clusterin in human renal diseases. 
  • Expression of differentiation antigens by hybrids of human lymphoblastoid cells. 
  • Expression of human fetal brain antigens by human tumors of neuroectodermal origin as defined by monoclonal antibodies. 
  • Expression of major histocompatibility complex class I antigens in normal and transformed rat thyroid epithelial cell lines. 
  • Expression of specific keratin markers by rabbit corneal, conjunctival, and esophageal epithelia during vitamin A deficiency. 
  • Expression of terminin in the rat brain during neuronal differentiation. 
  • Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. 
  • Expression of the CD7 ligand K-12 in human thymic epithelial cells: regulation by IFN-gamma. 
  • Expression of the cell adhesion molecule CD44 in gastric adenocarcinomas. 
  • Expression of the human leukocyte adhesion molecule, LAM1. Identity with the TQ1 and Leu-8 differentiation antigens. 
  • Expression, distribution, and biochemistry of human CD39. Role in activation-associated homotypic adhesion of lymphocytes. 
  • Extra-intestinal Hodgkin's lymphoma in a Crohn's disease patient on long-term azathioprine and infliximab therapy. 
  • Extracellular matrix disruption and pain after eccentric muscle action. 
  • FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. 
  • Facilitated PCI in patients with ST-elevation myocardial infarction. 
  • Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. 
  • Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. 
  • Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome. 
  • Factor IXa inhibitors as novel anticoagulants. 
  • Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: lessons from APEX-AMI. 
  • Failure of monoclonal antibodies against tumor associated antigens to improve tumor targeting of LAK cells in a model of rat colon carcinoma. 
  • Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient? 
  • Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. 
  • Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. 
  • Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis. 
  • Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. 
  • Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial). 
  • Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. 
  • Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. 
  • Final results of the ReoPro readministration registry. 
  • Finding the right job for the tool: alemtuzumab and its role in renal transplantation. 
  • Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. 
  • First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach. 
  • First report of keratitis in familial cold autoinflammatory syndrome. 
  • First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Doses of NTM-1633, a Novel Mixture of Monoclonal Antibodies against Botulinum Toxin E. 
  • First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. 
  • Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines. 
  • Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. 
  • Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. 
  • Fluorine-18 labeling of monoclonal antibodies and fragments with preservation of immunoreactivity. 
  • Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. 
  • From the editor: A run of success in treating atherosclerotic vascular disease. 
  • From the editor: Confronting a pandemic or two. 
  • Function and evolutionary conservation of distinct epitopes on the leukocyte adhesion molecule-1 (TQ-1, Leu-8) that regulate leukocyte migration. 
  • Function of the LFA-1 and T4 molecules in the direct activation of resting human B lymphocytes by T lymphocytes. 
  • Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. 
  • Functional association of CD7 with phosphatidylinositol 3-kinase: interaction via a YEDM motif. 
  • Functional impairment in protein kinase C by RACK1 (receptor for activated C kinase 1) deficiency in aged rat brain cortex. 
  • Functional interrogation and mining of natively paired human VH:VL antibody repertoires. 
  • Functional selection of protease inhibitory antibodies. 
  • Further characterization of erythrocyte p80 and the membrane protein defect of In(Lu) Lu(a-b-) erythrocytes. 
  • GD3 expression by cultured human tumor cells of neuroectodermal origin. 
  • GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice. 
  • Gamma (immune) interferon produced by leukocytes from a patients with a T cell proliferation disease. 
  • Gastrulation in the sea urchin embryo requires the deposition of crosslinked collagen within the extracellular matrix. 
  • Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). 
  • Gemtuzumab ozogamicin: is there room for salvage? 
  • Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Generating monoclonal antibodies to neuronal antigens. 
  • Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa. 
  • Generation and characterization of anti-Adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies. 
  • Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. 
  • Generation of human IgG, IgA, and IgM anti-melanoma monoclonal antibodies utilizing lymphocytes of an actively immunized melanoma patient. 
  • Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. 
  • Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. 
  • Glioma-associated antigens defined by monoclonal antibodies against an avian sarcoma virus-induced rat astrocytoma. 
  • GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins. 
  • Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors). 
  • Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists. 
  • Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. 
  • Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. 
  • Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. 
  • Good and bad memories following rituximab therapy. 
  • Granular presence of terminin is the marker to distinguish between the senescent and quiescent states. 
  • Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors. 
  • Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines. 
  • Growth factor receptors as molecular targets for cancer diagnosis and therapy. 
  • Gynecologic tumor markers. 
  • HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. 
  • HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. 
  • HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. 
  • HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. 
  • HIV-1 envelope glycoprotein trimers display open quaternary conformation when bound to the gp41 membrane-proximal external-region-directed broadly neutralizing antibody Z13e1. 
  • HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. 
  • HIV-1 neutralization by chimeric CD4-CG10 polypeptides fused to human IgG1. 
  • HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide. 
  • HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. 
  • HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. 
  • HLA antigen structural gene mutants selected with an allospecific monoclonal antibody. 
  • HLA class II molecules on monocytes regulate T cell proliferation through physical interaction in the CD3 activation pathway. 
  • HLA histocompatibility affects cardiac transplant rejection and may provide one basis for organ allocation. 
  • HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. 
  • Hairy cell leukemia: an elusive but treatable disease. 
  • Ham56-immunoreactive macrophages in untreated infiltrating gliomas. 
  • Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. 
  • Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. 
  • Hepatic cellular distribution of cytochrome P-450 IA1 in rainbow trout (Oncorhynchus mykiss): an immunohisto- and cytochemical study. 
  • Hepatocellular carcinoma occurring in a patient with Crohn's disease treated with both azathioprine and infliximab. 
  • Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review. 
  • Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors. 
  • Heterogeneity of acute lymphocytic leukemia cell surface markers as detected by monoclonal antibodies. 
  • Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction. 
  • Heterotropic modulation of selectin affinity by allosteric antibodies affects leukocyte rolling. 
  • Hidden biases in an observational study of bevacizumab beyond progression. 
  • High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). 
  • High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. 
  • High-density binding to Plasmodium falciparum circumsporozoite protein repeats by inhibitory antibody elicited in mouse with human immunoglobulin repertoire. 
  • High-frequency alloreactive T cells augment effector function of low-frequency CD8+ T-cell responses under CD28/CD154 blockade. 
  • High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use. 
  • High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. 
  • Histiocytes in familial and infection-induced/idiopathic hemophagocytic syndromes may exhibit phenotypic differences. 
  • Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. 
  • Hodgkin's lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis. 
  • Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. 
  • How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. 
  • How does alemtuzumab affect long-term graft and patient outcomes after deceased-donor kidney transplantation? 
  • Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. 
  • Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. 
  • Human T cell antigen expression by primate T cells. 
  • Human T cell antigen expression during the early stages of fetal thymic maturation. 
  • Human T cell receptor gamma delta structure. 
  • Human T lymphocyte antigens as defined by monoclonal antibodies. 
  • Human T-cell leukemia/lymphoma virus: studies of host-virus interaction. 
  • Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. 
  • Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. 
  • Human chorionic gonadotropin increases the concentration of macrophages in neonatal rat testis. 
  • Human colonic sulfomucin identified by a specific monoclonal antibody. 
  • Human colorectal carcinomas specifically accumulate Mr 42,000 ubiquitin-conjugated cytokeratin 8 fragments. 
  • Human erythrocyte acetylcholinesterase bears the Yta blood group antigen and is reduced or absent in the Yt(a-b-) phenotype. 
  • Human erythrocyte antigens. III. Characterization of a panel of murine monoclonal antibodies that react with human erythrocyte and erythroid precursor membranes. 
  • Human erythrocyte antigens. Regulation of expression of a novel erythrocyte surface antigen by the inhibitor Lutheran In(Lu) gene. 
  • Human fetal brain antigen expression common to tumors of neuroectodermal tissue origin. 
  • Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. 
  • Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. 
  • Human lymphocyte differentiation antigens HB-10 and HB-11. I. Ontogeny of antigen expression. 
  • Human lymphocyte differentiation antigens HB-10 and HB-11. II. Differential production of B cell growth and differentiation factors by distinct helper T cell subpopulations. 
  • Human malignant and mitogen-transformed cells contain retroviral P15E-related antigen. 
  • Human medullary thymocyte p80 antigen and In(Lu)-related p80 antigen reside on the same protein. 
  • Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain. 
  • Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. 
  • Human postnatal CD4- CD8- CD3- thymic T cell precursors differentiate in vitro into T cell receptor delta-bearing cells. 
  • Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients. 
  • Human red cell antigens. IV. The abnormal sialoglycoprotein of Gerbich-negative red cells. 
  • Human spleen contains phenotypic subsets of macrophages and dendritic cells that occupy discrete microanatomic locations. 
  • Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. 
  • Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. 
  • Hyperthermic modulation of radiolabelled antibody uptake in a human glioma xenograft and normal tissues. 
  • ICAM-1 (CD54) expression on B lymphocytes is associated with their costimulatory function and can be increased by coactivation with IL-1 and IL-7. 
  • ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging. 
  • IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. 
  • IFN-gamma dictates allograft fate via opposing effects on the graft and on recipient CD8 T cell responses. 
  • IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria. 
  • IL-10 induces regulatory T cell apoptosis by up-regulation of the membrane form of TNF-alpha. 
  • IL-2, IL-4, and IFN-gamma gene expression versus secretion in superantigen-activated T cells. Distinct requirement for costimulatory signals through adhesion molecules. 
  • IL-21 Biased Alemtuzumab Induced Chronic Antibody-Mediated Rejection Is Reversed by LFA-1 Costimulation Blockade. 
  • IL-6 and ovarian cancer--letter. 
  • Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells. 
  • Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. 
  • Identification and localization of a possible rhodopsin in the echinoderms Asterias forbesi (Asteroidea) and Ophioderma brevispinum (Ophiuroidea). 
  • Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases. 
  • Identification of a common epitope between enterovirus 71 and human MED25 proteins which may explain virus-associated neurological disease. 
  • Identification of a putative second T-cell receptor. 
  • Identification of a secreted Mr 95,000 glycoprotein in human melanocytes and melanomas by a melanocyte specific monoclonal antibody. 
  • Identification of a synaptic vesicle-specific membrane protein with a wide distribution in neuronal and neurosecretory tissue. 
  • Identification of a synthetic peptide that mimics an HIV glycoprotein 120 envelope conformational determinant exposed following ligation of glycoprotein 120 by CD4. 
  • Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. 
  • Identification of functional regions on the tail of Acanthamoeba myosin-II using recombinant fusion proteins. I. High resolution epitope mapping and characterization of monoclonal antibody binding sites. 
  • Identification of human and rodent thymic epithelium using tetanus toxin and monoclonal antibody A2B5. 
  • Identification of human erythrocyte blood group antigens on the C3b/C4b receptor. 
  • Identification of rat yolk sac target protein of teratogenic antibodies, gp280, as intrinsic factor-cobalamin receptor. 
  • Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. 
  • Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand. 
  • Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress. 
  • Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. 
  • Idiotypic analysis of a monoclonal anti-Sm antibody. 
  • Idiotypic analysis of a monoclonal anti-Sm antibody. II. Strain distribution of a common idiotypic determinant and its relationship to anti-Sm expression. 
  • Idiotypic cross-reaction between MRL autoantibodies and a BALB/c myeloma. 
  • Idiotypic cross-reaction between MRL monoclonal autoantibodies with different antigen specificity. 
  • Idiotypic determinants used in the analysis of antibody diversification and as regulatory targets. 
  • IgA-binding structures in dermatitis herpetiformis skin are independent of elastic-microfibrillar bundles. 
  • IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. 
  • IgG antinuclear antibodies with cross-reactive rheumatoid factor activity. 
  • IgG binding of monoclonal anti-nuclear antibodies from MRL-lpr/lpr mice. 
  • Immature human thymocytes can be driven to differentiate into nonlymphoid lineages by cytokines from thymic epithelial cells. 
  • Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. 
  • Immune Checkpoint Inhibitors Do Not Increase Short-Term Risk of Hypertension in Cancer Patients: a Systematic Literature Review and Meta-Analysis. 
  • Immune Checkpoint Inhibitors for Brain Metastases. 
  • Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa. 
  • Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas. 
  • Immune recognition of DNA in SLE. 
  • Immune response of chimpanzee to purified melanoma 250 kilodalton tumor-associated antigen. 
  • Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. 
  • Immune status assay (ISA): a noninvasive procedure for studying allograft rejection. 
  • Immune-related Neurological Symptoms in an Adolescent Patient Receiving the Checkpoint Inhibitor Nivolumab. 
  • Immunoaffinity purification of epitope-tagged human beta 2-adrenergic receptor to homogeneity. 
  • Immunoaffinity purification of human O6-alkylguanine-DNA alkyltransferase using newly developed monoclonal antibodies. 
  • Immunobiology of human gliomas. 
  • Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein. 
  • Immunochemical proof that a novel rearranging gene encodes the T cell receptor delta subunit. 
  • Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. 
  • Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. 
  • Immunocytochemical localization of photopigments in cephalopod retinae. 
  • Immunodiagnosis of human malignancy. 
  • Immunodiagnosis of tumors in vivo using radiolabeled monoclonal antibody A2B5. 
  • Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins. 
  • Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein. 
  • Immunohistochemical analysis of statin in colorectal adenocarcinoma, polyps, and normal mucosa. 
  • Immunohistochemical analysis of the pathogenesis of posterior polymorphous dystrophy. 
  • Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. 
  • Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors. 
  • Immunohistochemical expression of monoclonal antibody 43-9F in testicular germ cell tumours. 
  • Immunohistochemical expression of mutant p53 oncogene in transitional mucosa adjacent to human colon cancer. 
  • Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of four commercial antibodies. 
  • Immunolocalization of monoclonal antibody-defined extracellular matrix antigens in human brain tumors. 
  • Immunologic considerations in composite tissue transplantation: overview. 
  • Immunomagnetic selection of purified monocyte and lymphocyte populations from peripheral blood mononuclear cells following cryopreservation. 
  • Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. 
  • Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation. 
  • Immunoreactivity of apolipoprotein B-100 in oxidatively modified low density lipoprotein. 
  • Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. 
  • Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer. 
  • Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. 
  • Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer. 
  • Immunotherapy and monoclonal antibody therapies. 
  • Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma. 
  • Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. 
  • Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. 
  • Immunotoxin FN18-CRM9 induces stronger T cell signaling than unconjugated monoclonal antibody FN18. 
  • Immunotoxin-treated rhesus monkeys: a model for renal allograft chronic rejection. 
  • Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. 
  • Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. 
  • Impact of Leukocyte Function-Associated Antigen-1 Blockade on Endogenous Allospecific T Cells to Multiple Minor Histocompatibility Antigen Mismatched Cardiac Allograft. 
  • Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study. 
  • Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial. 
  • Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. 
  • Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model. 
  • Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). 
  • Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. 
  • Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. 
  • Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. 
  • Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. 
  • Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). 
  • Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. 
  • Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. 
  • Implications of leukoregulin to autologous tumor-specific human T-cell populations. 
  • Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. 
  • Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation. 
  • Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. 
  • Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model. 
  • Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. 
  • Improved synthesis of N-succinimidyl 4-[18F]fluorobenzoate and its application to the labeling of a monoclonal antibody fragment. 
  • Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. 
  • Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate. 
  • In patients with recent ACS and uncontrolled dyslipidemia, alirocumab reduced MACE regardless of previous CABG. 
  • In situ and systemic cellular immunity associated with orthotopic rat liver allograft acceptance or rejection. 
  • In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc. 
  • In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. 
  • In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. 
  • In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. 
  • In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP). 
  • In vitro biological activities of echinonectin. 
  • In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. 
  • In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonists c7E3 Fab on the activated clotting time. 
  • In vitro growth and phenotypic characterization of mesodermal-derived and epithelial components of normal and abnormal human thymus. 
  • In vitro neurogenesis by neuronal precursor cells derived from the adult songbird brain. 
  • In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of prostate carcinoma. 
  • In vivo and in vitro binding of iodinated monoclonal antibody A2B5 to RIN insulinoma cells. 
  • In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies. 
  • In vivo electroporation and non-protein based screening assays to identify antibodies against native protein conformations. 
  • In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. 
  • In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies. 
  • In vivo inhibition of renin by antirenin antibodies: potential experimental and clinical applications. 
  • In vivo tumor localization using tumor-specific monkey xenoantibody, alloantibody, and murine monoclonal xenoantibody. 
  • Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center. 
  • Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. 
  • Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb/IIIa platelet inhibitor era. 
  • Increase in TCR gamma delta T lymphocytes in synovia from rheumatoid arthritis patients with active synovitis. 
  • Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. 
  • Increased circulating Ia-antigen-bearing T cells in type I diabetes mellitus. 
  • Increased content of chondroitin sulfate proteoglycan in human colorectal carcinoma metastases compared with the primary tumor as determined by an anti-chondroitin-sulfate monoclonal antibody. 
  • Increased expression of sialyl-dimeric LeX antigen in liver metastases of human colorectal carcinoma. 
  • Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. 
  • Independently derived murine glomerular immune deposit-forming anti-DNA antibodies are encoded by near-identical VH gene sequences. 
  • Induction immunosuppression in liver transplantation: a review. 
  • Induction immunosuppression. 
  • Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. 
  • Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses. 
  • Induction of T cell CD7 gene transcription by nonmitogenic ionomycin-induced transmembrane calcium flux. 
  • Induction of a nonproductive conformational change in gp120 by a small molecule HIV type 1 entry inhibitor. 
  • Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. 
  • Induction of transplantation tolerance in non-human primate preclinical models. 
  • Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. 
  • Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. 
  • Inefficient dystrophin expression after cord blood transplantation in Duchenne muscular dystrophy. 
  • Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. 
  • Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. 
  • Infiltrating cell phenotypes and patterns associated with hepatic allograft rejection or acceptance. 
  • Inflammation, platelets, and glycoprotein IIb/IIIa inhibitors. 
  • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. 
  • Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. 
  • Infliximab for the treatment of adults with psoriasis. 
  • Infliximab for the treatment of early rheumatoid arthritis. 
  • Infliximab in active early rheumatoid arthritis. 
  • Infliximab maintenance therapy for fistulizing Crohn's disease. 
  • Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. 
  • Infliximab treatment for rheumatic disease: clinical and radiological efficacy. 
  • Infliximab treatment maintains employability in patients with early rheumatoid arthritis. 
  • Influence of assay conditions on ELISA determinations of anti-DNA antibodies. 
  • Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody. 
  • Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody. 
  • Inhibition by anti-HLA class II monoclonal antibodies of monoclonal antibody OKT3-induced T cell proliferation. Studies at the mRNA level. 
  • Inhibition of HIV type 1 infection of mononuclear phagocytes by anti-CD44 antibodies. 
  • Inhibition of acanthamoeba actomyosin-II ATPase activity and mechanochemical function by specific monoclonal antibodies. 
  • Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. 
  • Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery. 
  • Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). 
  • Inhibition of human corneal epithelium with immunotoxin 454A12-rRA. 
  • Inhibition of human subconjunctival fibroblast proliferation by immunotoxin. 
  • Inhibition of leukocyte L-selectin function with a monoclonal antibody attenuates reperfusion injury to the rabbit ear. 
  • Inhibition of proliferating lens epithelium with antitransferrin receptor immunotoxin. 
  • Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. 
  • Inhibition of the growth of human melanoma metastases in nude mice by melanoma-specific murine monoclonal antibody. 
  • Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. 
  • Inhibition of αvβ6 promotes acute renal allograft rejection in nonhuman primates. 
  • Inhibitors of monocyte responses to chemotaxins are present in human cancerous effusions and react with monoclonal antibodies to the P15(E) structural protein of retroviruses. 
  • Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. 
  • Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. 
  • Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. 
  • Innate and adaptive receptors interact to balance humoral immunity. 
  • Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. 
  • Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library. 
  • Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. 
  • Interaction of a 60-kilodalton D-mannose-containing salivary glycoprotein with type 1 fimbriae of Escherichia coli. 
  • Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. 
  • Interactions between precipitating and nonprecipitating antibodies in the formation of immune complexes. 
  • Interference of thrombin in immunological assays for hirudin specific antibodies. 
  • Interinstitutional variation in the use of abciximab for percutaneous coronary intervention. 
  • Intestinal Inflammation Promotes MDL-1+ Osteoclast Precursor Expansion to Trigger Osteoclastogenesis and Bone Loss. 
  • Intraportal injection of monoclonal antibody in nude mice bearing hepatic metastases. 
  • Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. 
  • Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. 
  • Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model. 
  • Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. 
  • Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques. 
  • Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas. 
  • Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. 
  • Investigations using a novel monoclonal antibody to the glycosylphosphatidylinositol-anchored protein that carries Gregory, Holley, and Dombrock blood group antigens. 
  • Investigative studies in the diagnosis and treatment of melanoma. 
  • Involvement of protein tyrosine phosphorylation in immunotoxin effects on T lymphocytes. 
  • Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. 
  • Irradiation and immunotherapy: From concept to the clinic. 
  • Is renin a factor in the etiology of essential hypertension? 
  • Is visual interpretation of coronary epicardial flow reliable in patients with ST-elevation myocardial infarction undergoing primary angioplasty? Insights from the angiographic substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. 
  • Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields. 
  • Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum. 
  • Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. 
  • Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. 
  • Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. 
  • Isolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes. 
  • Isolation of monoclonal antibodies with predetermined conformational epitope specificity. 
  • Isolation of novel EGFR-specific VHH domains. 
  • Kappa editing rescues autoreactive B cells destined for deletion in mice transgenic for a dual specific anti-laminin Ig. 
  • Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. 
  • Kidney and pancreas transplantation at Wake Forest University Baptist Medical Center. 
  • L-selectin (CD62L) blockade does not impair peritoneal neutrophil emigration or subcutaneous host defense to bacteria in rabbits. 
  • L-selectin dimerization enhances tether formation to properly spaced ligand. 
  • L-selectin ligands expressed by human leukocytes are HECA-452 antibody-defined carbohydrate epitopes preferentially displayed by P-selectin glycoprotein ligand-1. 
  • L-selectin or ICAM-1 deficiency reduces an immediate-type hypersensitivity response by preventing mast cell recruitment in repeated elicitation of contact hypersensitivity. 
  • LFA-1 binding site in ICAM-3 contains a conserved motif and non-contiguous amino acids. 
  • LFA-1-specific therapy prolongs allograft survival in rhesus macaques. 
  • Labeling Monoclonal Antibody with α-emitting 211At at High Activity Levels via a Tin Precursor. 
  • Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands. 
  • Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. 
  • Labeling monoclonal antibodies with halogen nuclides. 
  • Labeling proteins using aryl iodide acylation agents: influence of meta vs para substitution on in vivo stability. 
  • Labeling proteins with fluorine-18 using N-succinimidyl 4-[18F]fluorobenzoate. 
  • Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. 
  • Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. 
  • Lactotetraose series ganglioside 3',6'-isoLD1 in tumors of central nervous and other systems in vitro and in vivo. 
  • Laminar asymmetry in the distribution of choline acetyltransferase-immunoreactive neurons in the retina of the tree shrew (Tupaia belangeri). 
  • Laminin mediates tethering and spreading of colon cancer cells in physiological shear flow. 
  • Large subretinal hemorrhage after intravitreal bevacizumab (Avastin) for age-related macular degeneration. 
  • Late outcomes after intervention of vein grafts in diabetics with abciximab use. 
  • Leprosy in a mangabey monkey--naturally acquired infection. 
  • Leukemia-associated arthritis: identification of leukemic cells in synovial fluid using monoclonal and polyclonal antibodies. 
  • Leukemias and lymphomas of thymic differentiation. 
  • Leukocyte adhesion molecule-1 (LAM-1, L-selectin) interacts with an inducible endothelial cell ligand to support leukocyte adhesion. 
  • Life threatening liver disease during treatment with monoclonal antibodies. 
  • Ligand binding to the LFA-3 cell adhesion molecule induces IL-1 production by human thymic epithelial cells. 
  • Ligation of L-selectin through conserved regions within the lectin domain activates signal transduction pathways and integrin function in human, mouse, and rat leukocytes. 
  • Ligation of MHC class I and class II molecules can lead to heterologous desensitization of signal transduction pathways that regulate homotypic adhesion in human lymphocytes. 
  • Ligation of cell surface GRP78 with antibody directed against the COOH-terminal domain of GRP78 suppresses Ras/MAPK and PI 3-kinase/AKT signaling while promoting caspase activation in human prostate cancer cells. 
  • Ligation of low-density lipoprotein receptor-related protein with antibodies elevates intracellular calcium and inositol 1,4, 5-trisphosphate in macrophages. 
  • Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain. 
  • Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model. 
  • Localization of collagenase mRNA in rheumatoid arthritis synovium by in situ hybridization histochemistry. 
  • Localization of fluorine-18-labeled Mel-14 monoclonal antibody F(ab')2 fragment in a subcutaneous xenograft model. 
  • Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras. 
  • Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis. 
  • Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study. 
  • Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb. 
  • Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. 
  • Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial. 
  • Long-term retinal toxicity of intravitreal commercially available preserved triamcinolone acetonide (Kenalog) in rabbit eyes. 
  • Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program. 
  • Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. 
  • Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. 
  • Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. 
  • Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report. 
  • Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. 
  • Lung-specific overexpression of CC chemokine ligand (CCL) 2 enhances the host defense to Streptococcus pneumoniae infection in mice: role of the CCL2-CCR2 axis. 
  • Lupus autoantibodies interact directly with distinct glomerular and vascular cell surface antigens. 
  • Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. 
  • Lymphocyte subsets in Chediak-Higashi patients. 
  • Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. 
  • Lysosomal integral membrane proteins exhibit region and cell type specific distribution in the epididymis of the adult rat. 
  • MARCO is the major binding receptor for unopsonized particles and bacteria on human alveolar macrophages. 
  • MAb for symptomatic COVID-19 in correctional facilities: an important opportunity. 
  • MRP3: a molecular target for human glioblastoma multiforme immunotherapy. 
  • MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. 
  • Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. 
  • Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. 
  • Management of bronchiolitis in infants and children. 
  • Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46. 
  • Mapping of pseudouridine residues on cellular and viral transcripts using a novel antibody-based technique. 
  • Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. 
  • Measles Virus Hemagglutinin epitopes immunogenic in natural infection and vaccination are targeted by broad or genotype-specific neutralizing monoclonal antibodies. 
  • Measuring the Impact of Targeting FcRn-Mediated IgG Recycling on Donor-Specific Alloantibodies in a Sensitized NHP Model. 
  • Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. 
  • Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. 
  • Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of Mac-1(CD11b/CD18) and urokinase receptor (CD87). 
  • Mechanisms of tolerance induced by an immunotoxin against CD3 epsilon in a rhesus kidney allograft model. 
  • Melanoma brain metastasis: overview of current management and emerging targeted therapies. 
  • Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies. 
  • Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. 
  • Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy. 
  • Merosin promotes neurite growth and Schwann cell migration in vitro and nerve regeneration in vivo: evidence using an antibody to merosin, ARM-1. 
  • Mesothelioma vs. adenocarcinoma. 
  • Metabolism of levo-alpha-Acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites. 
  • Metastatic behavior and cell surface properties of HT-29 human colon carcinoma variant cells selected for their differential expression of sialyl-dimeric Le(x)-antigen. 
  • Metastatic potential of colon carcinoma. Expression of ABO/Lewis-related antigens. 
  • Method for radioiodination of proteins using N-succinimidyl 3-hydroxy-4-iodobenzoate. 
  • Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. 
  • Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. 
  • Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review. 
  • Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF. 
  • Modular complement assemblies for mitigating inflammatory conditions. 
  • Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105. 
  • Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer. 
  • Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. 
  • Modulation of murine herpes simplex virus type 1 retinitis in the uninoculated eye by CD4+ T lymphocytes. 
  • Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies. 
  • Modulation of the intracellular Ca2+ and inositol trisphosphate concentrations in murine T lymphocytes by the glycosylphosphatidylinositol-anchored protein sgp-60. 
  • Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide. 
  • Molecular abnormalities of human plasminogen isolated from synovial fluid of rheumatoid arthritis patients. 
  • Molecular analysis of highly enriched populations of T-cell-depleted monocytes. 
  • Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes. 
  • Molecular evidence of a genotypically novel large T-cell lymphoma after anti-CD4 therapy for refractory mycosis fungoides. 
  • Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. 
  • Molecular mapping of functional domains of the leukocyte receptor for endothelium, LAM-1. 
  • Molecular staging and the selection of therapy for non-small cell lung cancer. 
  • Molecular studies of human renin structure and synthesis using monoclonal antibodies. 
  • Molecular testing in colorectal cancer: diagnosis of Lynch syndrome and personalized cancer medicine. 
  • Monensin enhances the cytotoxic effect of antitransferrin receptor immunotoxin on cultured RPE cells. 
  • Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. 
  • Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. 
  • Monoclonal antibodies against human T cell leukemia-lymphoma virus (HTLV) p24 internal core protein. Use as diagnostic probes and cellular localization of HTLV. 
  • Monoclonal antibodies against the CD44 [In(Lu)-related p80], and Pgp-1 antigens in man recognize the Hermes class of lymphocyte homing receptors. 
  • Monoclonal antibodies as molecular probes to study structural heterogeneity between human and animal renins and other aspartyl proteinases. 
  • Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults. 
  • Monoclonal antibodies binding renal renin. 
  • Monoclonal antibodies demonstrate limited structural homology between myosin isozymes from Acanthamoeba. 
  • Monoclonal antibodies for brain tumour treatment. 
  • Monoclonal antibodies reactive with epitopes restricted to glial fibrillary acidic proteins of several species. 
  • Monoclonal antibodies reactive with human T cell lymphotropic virusI (HTLVI) p19 internal core protein: cross-reactivity with normal tissues and differential reactivity with HTLV types I and II. 
  • Monoclonal antibodies reveal receptor specificity among G-protein-coupled receptor kinases. 
  • Monoclonal antibodies specific for human renin. 
  • Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41. 
  • Monoclonal antibodies that detect biochemical markers of arthritis in humans. 
  • Monoclonal antibodies to CD2 and lymphocyte function-associated antigen 3 inhibit human thymic epithelial cell-dependent mature thymocyte activation. 
  • Monoclonal antibodies to T-helper/inducer and T-suppressor/cytotoxic lymphocyte subsets recognize antigens on splenic sinusoidal lining cells. 
  • Monoclonal antibodies to a human islet cell surface glycoprotein: 4F2 and LC7-2. 
  • Monoclonal antibodies to antigens abnormally expressed in breast cancer. 
  • Monoclonal antibodies to different epitopes on a prostate tumor-associated antigen. Implications for immunotherapy. 
  • Monoclonal antibodies to epitopes on different regions of the 200 000 dalton neurofilament protein. Probes for the geometry of the filament. 
  • Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors. 
  • Monoclonal antibodies to human cartilage oligomeric matrix protein: epitope mapping and characterization of sandwich ELISA. 
  • Monoclonal antibodies to human primary uveal melanomas demonstrate tumor heterogeneity. 
  • Monoclonal antibodies to malignant human gliomas. 
  • Monoclonal antibodies to the common gamma-chain as cytokine receptor antagonists in vivo: effect on intrathymic and intestinal intraepithelial T lymphocyte development. 
  • Monoclonal antibodies to tissue-associated antigens as antitumor reagents. 
  • Monoclonal antibodies to tissue-specific cell surface antigens. I. Characterization of an antibody to a prostate tissue antigen. 
  • Monoclonal antibodies to uveal melanoma. 
  • Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century? 
  • Monoclonal antibody 4F2 reactive with basal layer keratinocytes: studies in the normal and a hyperproliferative state. 
  • Monoclonal antibody F(ab')2 fragment labeled with N-succinimidyl 2,4-dimethoxy-3-halobenzoates: in vivo comparison of iodinated and astatinated fragments. 
  • Monoclonal antibody OKT3-induced T cell proliferation: differential role of HLA class II determinants expressed by T cells and monocytes. 
  • Monoclonal antibody against human T cell leukemia virus p19 defines a human thymic epithelial antigen acquired during ontogeny. 
  • Monoclonal antibody against human colonic sulfomucin: immunochemical detection of its binding sites in colonic mucosa, colorectal primary carcinoma, and metastases. 
  • Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. 
  • Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. 
  • Monoclonal antibody defines human cell surface protein p80 on intrathymic T cells. 
  • Monoclonal antibody definition of T cell acute leukemia: a Pediatric Oncology Group study. 
  • Monoclonal antibody interaction with the third immunoglobulin-like domain of N-CAM is sufficient to cause cell migration. 
  • Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis. 
  • Monoclonal antibody recognizing a unique Rh-related specificity. 
  • Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. 
  • Monoclonal antibody therapy in the treatment of non-Hodgkin lymphoma. 
  • Monoclonal antibody therapy of human gliomas: current status and future approaches. 
  • Monoclonal rheumatoid factors from B6-lpr/lpr mice. 
  • Monocyte attachment to activated human vascular endothelium in vitro is mediated by leukocyte adhesion molecule-1 (L-selectin) under nonstatic conditions. 
  • Monocyte-derived CD40 expression is regulated by interferon-γ/interferon-γ receptor-1 pathway when acting as a bridge during their interaction with T cells and allogeneic endothelial cells. 
  • Mononuclear cells from patients with the hyper-IgE syndrome produce little IgE when they are stimulated with recombinant human interleukin-4. 
  • Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model. 
  • Morphomics predicts response to ipilimumab in patients with stage IV melanoma. 
  • Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. 
  • Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. 
  • Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. 
  • Mouse CD20 expression and function. 
  • Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization. 
  • Multi-analyte analysis system using an antibody-based biochip. 
  • Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. 
  • Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study. 
  • Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. 
  • Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe). 
  • Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. 
  • Multiple assay characterization of murine monoclonal antimelanoma antibodies. 
  • Multiple gamma c-dependent cytokines regulate T-cell development. 
  • Multiple-analyte fluoroimmunoassay using an integrated optical waveguide sensor. 
  • Multisite comparison of methods for the quantitation of the surface expression of CD38 on CD8(+) T lymphocytes. The ACTG Advanced Flow Cytometry Focus Group. 
  • Murine CD7 shares antigenic cross-reactivity with HSP-60. 
  • Murine malignant cells synthesize a 19,000-dalton protein that is physicochemically and antigenically related to the immunosuppressive retroviral protein, P15E. 
  • Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo. 
  • Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease. 
  • Murine monoclonal antibodies specific for conserved and non-conserved antigenic determinants of the human and murine Ku autoantigens. 
  • Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. 
  • Mutant p53 as an Antigen in Cancer Immunotherapy. 
  • Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. 
  • Myosin from human erythrocytes. 
  • N-succinimidyl 3-[(131)I]iodo-4-phosphonomethylbenzoate ([(131)I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs. 
  • N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At. 
  • N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate: synthesis and potential utility for the radioiodination of monoclonal antibodies. 
  • N-succinimidyl 5-(trialkylstannyl)-3-pyridinecarboxylates: a new class of reagents for protein radioiodination. 
  • N-terminal and central regions of the human CD44 extracellular domain participate in cell surface hyaluronan binding. 
  • N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. 
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. 
  • NK and LAK susceptibility varies inversely with target cell MHC class I antigen expression in a rat epithelial tumour system. 
  • Necrosis and apoptosis of tumor cells in embolized meningiomas: histopathology and P53, BCL-2, CD-68 immunohistochemistry. 
  • Neoadjuvant use of ipilimumab in locally advanced melanoma. 
  • Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies. 
  • Neurite outgrowth from progeny of epidermal growth factor-responsive hippocampal stem cells is significantly less robust than from fetal hippocampal cells following grafting onto organotypic hippocampal slice cultures: effect of brain-derived neurotrophic factor. 
  • Neurite outgrowth is enhanced by anti-idiotypic monoclonal antibodies to the ganglioside GM1. 
  • Neuro-ophthalmic side effects of molecularly targeted cancer drugs. 
  • Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. 
  • Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. 
  • Neutralizing antibodies take a swipe at HIV in vivo. 
  • New combinations in metastatic colorectal cancer: what are our expectations? 
  • New drugs in prostate cancer. 
  • New prospects for autoimmune disease therapy: B cells on deathwatch. 
  • New therapeutic options in the management of childhood brain tumors. 
  • New tools for studying microglia in the mouse and human CNS. 
  • Newborn discordant cardiac xenotransplantation in primates: a model of natural antibody depletion. 
  • Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. 
  • Niacin-like reaction to infliximab infusion in systemic juvenile rheumatoid arthritis. 
  • Nitric oxide synthase is an active enzyme in the spiral ganglion cells of the rat cochlea. 
  • Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. 
  • Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). 
  • Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. 
  • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. 
  • Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. 
  • Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. 
  • Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. 
  • Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. 
  • Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. 
  • Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. 
  • Nivolumab: Immunotherapy in Malignant Melanoma. 
  • Non-redundant roles for interleukin-1 alpha and interleukin-1 beta in regulating human IgG2. 
  • Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab. 
  • Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. 
  • Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens. 
  • Novel Monoclonal Antibodies for Studies of Human and Rhesus Macaque Secretory Component and Human J-Chain. 
  • Novel diagnostic assays for heparin-induced thrombocytopenia. 
  • Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. 
  • Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. 
  • Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy. 
  • Novel therapeutic approaches to advanced prostate cancer. 
  • Novel--and "neu"--therapeutic possibilities for heart failure. 
  • Nuclear oncoprotein expression as a function of lineage, differentiation stage, and proliferative status of normal human hematopoietic cells. 
  • Nuclear pore complex proteins mark the implantation window in human endometrium. 
  • OKT3 vs ALG induction therapy in combined pancreas-kidney transplantation. 
  • OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. 
  • Obesity following kidney transplantation and steroid avoidance immunosuppression. 
  • Obligatory role for cooperative signaling by pre-TCR and Notch during thymocyte differentiation. 
  • Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. 
  • Occurrence of lacto series gangliosides 3'-isoLM1 and 3',6'-isoLD1 in human gliomas in vitro and in vivo. 
  • Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. 
  • Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. 
  • On the mechanism of acetylcholine receptor accumulation at newly formed synapses on chick myotubes. 
  • Ontogeny of the basal lamina in the sea urchin embryo. 
  • Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. 
  • Optical imaging of cervical pre-cancers with structured illumination: an integrated approach. 
  • Optimization of immunolabeled plasmonic nanoparticles for cell surface receptor analysis. 
  • Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. 
  • Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. 
  • Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. 
  • Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. 
  • Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). 
  • Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. 
  • Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. 
  • Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial. 
  • Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. 
  • Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization. 
  • Overexpression of cell surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix. 
  • Overexpression of human carcinoma-associated antigen in esophageal adenocarcinoma and its precursor lesions. 
  • Overexpression of human carcinoma-associated antigen in urothelial carcinoma of the bladder. 
  • P- and L-selectin mediate distinct but overlapping functions in endotoxin-induced leukocyte-endothelial interactions in the rat mesenteric microcirculation. 
  • PCI at non-PCI centres: immediate or rescue? 
  • PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease. 
  • PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model. 
  • PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. 
  • PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'. 
  • PEGylated gold nanoparticles conjugated to monoclonal F19 antibodies as targeted labeling agents for human pancreatic carcinoma tissue. 
  • PET concerns in bevacizumab treatment. 
  • PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment. 
  • PF4-HIT antibody (KKO) complexes activate broad innate immune and inflammatory responses. 
  • PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. 
  • PTEN reconstitution alters glioma responses to c-Met pathway inhibition. 
  • Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. 
  • Palliative treatment of metastatic colorectal cancer: what is the optimal approach? 
  • Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. 
  • Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. 
  • Paraoxon toxicity is not potentiated by prior reduction in blood acetylcholinesterase. 
  • Partial purification and characterization of a murine glioma-associated antigen defined by syngeneic rat monoclonal antibodies. 
  • Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission? 
  • Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. 
  • Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. 
  • Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer. 
  • Pediatric neuro-Behçet's disease responsive to adalimumab. 
  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. 
  • Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial. 
  • Peripheral blood mononuclear cells from patients with bullous pemphigoid have an increased frequency of response to synthetic peptides encoded by BPAG1. 
  • Persistent antibody depletion after rituximab in three children with autoimmune cytopenias. 
  • Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer. 
  • Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy. 
  • Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapy. 
  • Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial. 
  • Pexelizumab and the APEX AMI trial. 
  • Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. 
  • Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. 
  • Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. 
  • Pexelizumab: a novel therapy for myocardial ischemia-reperfusion. 
  • Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. 
  • Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. 
  • Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques. 
  • Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. 
  • Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. 
  • Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen. 
  • Pharmacokinetics of radiolabeled monoclonal antibody B6.2 in patients with metastatic breast cancer. 
  • Pharmacological blockade of a β(2)AR-β-arrestin-1 signaling cascade prevents the accumulation of DNA damage in a behavioral stress model. 
  • Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. 
  • Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. 
  • Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. 
  • Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. 
  • Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors. 
  • Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. 
  • Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. 
  • Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. 
  • Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report. 
  • Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. 
  • Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. 
  • Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery. 
  • Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. 
  • Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. 
  • Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. 
  • Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. 
  • Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. 
  • Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. 
  • Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. 
  • Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. 
  • Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. 
  • Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. 
  • Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). 
  • Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. 
  • Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. 
  • Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. 
  • Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. 
  • Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. 
  • Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. 
  • Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. 
  • Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. 
  • Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. 
  • Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. 
  • Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. 
  • Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. 
  • Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. 
  • Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. 
  • Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. 
  • Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung Cancer. 
  • Phenotypic Correlates of HIV-1 Macrophage Tropism. 
  • Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts. 
  • Phenotypic and functional characterization of human malignant T cells. 
  • Phenotypic characterization and ontogeny of components of the human thymic microenvironment. 
  • Phenotypic characterization and ontogeny of mesodermal-derived and endocrine epithelial components of the human thymic microenvironment. 
  • Phenotypic characterization of skin-infiltrating T cells in cutaneous T-cell lymphoma: comparison with benign cutaneous T-cell infiltrates. 
  • Phenotypic subpopulations of macrophages and dendritic cells in human spleen. 
  • Pillars Article: Identification of a Putative Second T-cell Receptor. Nature. 1986. 322: 145-149. 
  • Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. 
  • Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. 
  • Plasmacellular differentiation in extranodal marginal zone B cell lymphomas of the ocular adnexa: an analysis of the neoplastic plasma cell phenotype and its prognostic significance in 136 cases. 
  • Platelet function and pharmacologic inhibition. 
  • Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection. 
  • Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. 
  • Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition? 
  • Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies. 
  • Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. 
  • Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma. 
  • Polyclonal HIV envelope-specific breast milk antibodies limit founder SHIV acquisition and cell-associated virus loads in infant rhesus monkeys. 
  • Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. 
  • Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. 
  • Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. 
  • Polymyositis as a manifestation of chronic graft-versus-host disease. 
  • Polyspecific binding of Escherichia coli beta-galactosidase by murine antibodies to DNA. 
  • Polyspecific reactivity of a murine monoclonal antibody that binds to nuclear matrix-associated, chromatin-bound autoantigens. 
  • Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status. 
  • Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR. 
  • Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. 
  • Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. 
  • Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. 
  • Posttranslational modifications of tubulin in teleost photoreceptor cytoskeletons. 
  • Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. 
  • Potential of costimulation-based therapies for composite tissue allotransplantation. 
  • Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning. 
  • Power calculations for large multi-arm placebo-controlled studies of dichotomous outcomes. 
  • Power considerations for trials of two experimental arms versus a standard active control or placebo. 
  • Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. 
  • Preclinical evaluation and PET imaging of 18F-labeled Mel-14 F(ab')2 fragment in normal dogs. 
  • Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. 
  • Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. 
  • Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. 
  • Predictive factors for response to anti-thymocyte globulin in acquired aplastic anemia. 
  • Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). 
  • Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. 
  • Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. 
  • Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery. 
  • Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. 
  • Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. 
  • Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications. 
  • Preparation of monoclonal antibodies reactive to the endogenous small molecule, anandamide. 
  • Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. 
  • Prevention of herpes keratitis by monoclonal antibodies specific for discontinuous and continuous epitopes on glycoprotein D. 
  • Primate renal transplants using immunotoxin. 
  • Primate skin allotransplantation with anti-CD154 monotherapy. 
  • Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. 
  • Procedural and clinical outcomes after use of the glycoprotein IIb/IIIa inhibitor abciximab for saphenous vein graft interventions. 
  • Production and characterization of two human glioma xenograft-localizing monoclonal antibodies. 
  • Production of monoclonal antibody alpha Pro3 recognizing a human prostatic carcinoma antigen. 
  • Production of polyclonal and monoclonal antibodies to calmodulin and utilization of these immunological probes. 
  • Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. 
  • Progesterone receptors in the human heart and great vessels. 
  • Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients. 
  • Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. 
  • Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. 
  • Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. 
  • Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study. 
  • Prognostic marker analysis in pediatric intracranial ependymomas. 
  • Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. 
  • Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. 
  • Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). 
  • Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis. 
  • Progress in the treatment of rheumatoid arthritis. 
  • Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. 
  • Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. 
  • Proinflammatory cytokines increase in sepsis after anti-adhesion molecule therapy. 
  • Proliferation index in various stages of breast cancer determined by Ki-67 immunostaining. 
  • Proliferative activity at colonic anastomoses as determined by statin. A nonproliferation-specific nuclear protein. 
  • Proliferative activity of colonic mucosa at different distances from primary adenocarcinoma as determined by the presence of statin: a nonproliferation-specific nuclear protein. 
  • Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. 
  • Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. 
  • Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3. 
  • Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy-Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value. 
  • Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review. 
  • ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. 
  • Protection against Escherichia coli-induced urinary tract infections with hybridoma antibodies directed against type 1 fimbriae or complementary D-mannose receptors. 
  • Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. 
  • Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice. 
  • Protein radiohalogenation: observations on the design of N-succinimidyl ester acylation agents. 
  • Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individuals. 
  • Purging multidrug resistant cells from bone marrow. 
  • Purified lymphocyte function-associated antigen-3 (LFA-3) activates human thymocytes via the CD2 pathway. 
  • Quality control in the flow cytometric measurement of T-lymphocyte subsets: the multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study Group. 
  • RECISTing the Temptation to Prematurely Stop Nivolumab. 
  • Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. 
  • Radiohalogenation of a monoclonal antibody using an N-succinimidyl 3-(tri-n-butylstannyl)benzoate intermediate. 
  • Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. 
  • Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p185: comparison of iodogen and N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate radioiodination methods. 
  • Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14. 
  • Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. 
  • Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. 
  • Radioimmunotherapy with alpha-particle emitting radionuclides. 
  • Radioiodinated B6.2 monoclonal antibody: further characterization of a potential radiopharmaceutical for the identification of breast tumors. 
  • Radioiodinated antibody targeting of the HER-2/neu oncoprotein. 
  • Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. 
  • Radioiodination of a monoclonal antibody using N-succinimidyl 5-iodo-3-pyridinecarboxylate. 
  • Radioiodination of antibodies via N-succinimidyl 2,4-dimethoxy-3-(trialkylstannyl)benzoates. 
  • Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate. 
  • Radioiodination of proteins using N-succinimidyl 4-hydroxy-3-iodobenzoate. 
  • Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. 
  • Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. 
  • Radiolocalization of human pancreatic tumors in athymic mice by monoclonal antibody DU-PAN 1. 
  • Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. 
  • Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis. 
  • Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. 
  • Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. 
  • Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. 
  • Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. 
  • Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. 
  • Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. 
  • Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. 
  • Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. 
  • Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. 
  • Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. 
  • Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. 
  • Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. 
  • Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. 
  • Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. 
  • Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. 
  • Ranibizumab and bevacizumab for AMD. 
  • Ranibizumab and bevacizumab for neovascular age-related macular degeneration. 
  • Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. 
  • Ranibizumab for neovascular age-related macular degeneration. 
  • Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. 
  • Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. 
  • Rapid disappearance of statin, a nonproliferating and senescent cell-specific protein, upon reentering the process of cell cycling. 
  • Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems. 
  • Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. 
  • Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system. 
  • Reactivity of epidermal growth factor receptor monoclonal antibodies with human uterine tissues. 
  • Readministration of abciximab: interim report of the ReoPro readministration registry. 
  • Recognition of HLA-A2 mutant and variant target cells by an HLA-A2 allospecific human cytotoxic T lymphocyte line. 
  • Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. 
  • Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation. 
  • Reconstitution of a T cell receptor-stimulated plasma membrane calcium transporter: lack of dependence on inositol phosphates. 
  • Recovery of a human natural antibody against the noncollagenous-1 domain of type IV collagen using humanized models. 
  • Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. 
  • Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts. 
  • Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade. 
  • Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials. 
  • Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2). 
  • Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. 
  • Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. 
  • Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: kinetics and implications for diagnosis and therapy. 
  • Regulated exocytosis and sequential construction of the extracellular matrix surrounding the sea urchin zygote. 
  • Regulation of ZAP-70 intracellular localization: visualization with the green fluorescent protein. 
  • Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. 
  • Regulation of human CD44H and CD44E isoform binding to hyaluronan by phorbol myristate acetate and anti-CD44 monoclonal and polyclonal antibodies. 
  • Regulation of leukocyte migration by activation of the leukocyte adhesion molecule-1 (LAM-1) selectin. 
  • Regulation of the anti-Sm autoantibody response in systemic lupus erythematosus mice by monoclonal anti-Sm antibodies. 
  • Regulation of the immune response. II. Concomitant idiotope-specific enhancement and suppression can result in a phenotypically normal response. 
  • Regulation of the tyrosine kinase-dependent adhesion pathway in human lymphocytes through CD45. 
  • Regulatory B cell (B10 Cell) expansion during Listeria infection governs innate and cellular immune responses in mice. 
  • Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. 
  • Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease? 
  • Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. 
  • Relationship of the human erythrocyte Wrb antigen to an interaction between glycophorin A and band 3. 
  • Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. 
  • Relevance for neurobiology and neurooncology of antigens of malignant gliomas as defined by monoclonal antibodies. 
  • Removal of fibroblasts from human epithelial cell cultures with use of a complement fixing monoclonal antibody reactive with human fibroblasts and monocytes/macrophages. 
  • Renal Amyloidosis in Deficiency of Adenosine Deaminase 2: Successful Experience With Canakinumab. 
  • Renal allograft cell infiltrates associated with irreversible rejection. 
  • Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients. 
  • Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study. 
  • Reperfusion edema after lung transplantation: effect of daclizumab. 
  • Reply to Vanhove et al. 
  • Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown. 
  • Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction. 
  • Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. 
  • Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin': reply from the authors. 
  • Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. 
  • Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. 
  • Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). 
  • Retinoblastoma protein monoclonal antibodies with novel characteristics. 
  • Reversal of acute allograft rejection using immunotoxin. 
  • Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma. 
  • Rh-related antigen CD47 is the signal-transducer integrin-associated protein. 
  • Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. 
  • Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. 
  • Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. 
  • Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. 
  • Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. 
  • Rituximab in lymphocyte predominance Hodgkin's disease: a case series. 
  • Rituximab versus cyclophosphamide for ANCA-associated vasculitis. 
  • Role of HIV membrane in neutralization by two broadly neutralizing antibodies. 
  • Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model. 
  • Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. 
  • Roundtable panel discussion: the role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes. 
  • Ryk controls remapping of motor cortex during functional recovery after spinal cord injury. 
  • SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment. 
  • SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. 
  • SARS-CoV-2 Variants in Patients with Immunosuppression. 
  • SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. 
  • SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies. 
  • SP75 is encoded by the DP87 gene and belongs to a family of modular Dictyostelium discoideum outer layer spore coat proteins. 
  • ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. 
  • ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma. 
  • Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. 
  • Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab. 
  • Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. 
  • Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. 
  • Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. 
  • Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. 
  • Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. 
  • Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. 
  • Safety of abciximab administration during PCI of patients with previous stroke. 
  • Safety of bevacizumab in patients with metastatic breast cancer. 
  • Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B. 
  • Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. 
  • Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. 
  • Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. 
  • Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. 
  • Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. 
  • Science to practice: Molecular targeting with SPECT/CT and MR imaging in oncology--integration of functional and structural imaging. 
  • Sclerosing mesenteritis successfully treated with a TNF antagonist. 
  • Second international workshop on monoclonal antibodies and breast cancer. San Francisco, November 20-21, 1986. 
  • Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. 
  • Secukinumab (AIN-457) for the treatment of Psoriasis. 
  • Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor. 
  • Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display. 
  • Selection of patients with Hodgkin's disease and non-Hodgkin's lymphoma for bone marrow transplantation. 
  • Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. 
  • Selective inhibition of natural killer activity by the monoclonal antibodies OKT10 and VEP10 at the single cell level. 
  • Selective recognition of DNA antigenic determinants by murine monoclonal anti-DNA antibodies. 
  • Sensitive and specific detection of the 4B5 antigen in bronchial lavage specimens from patients with primary bronchogenic carcinoma. 
  • Sensitivity and specificity of phospho-Ser129 α-synuclein monoclonal antibodies. 
  • Separation of the acetylcholinesterase-deficient red cells in paroxysmal nocturnal hemoglobinuria. 
  • Sequential contribution of L- and P-selectin to leukocyte rolling in vivo. 
  • Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. 
  • Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. 
  • Serological and biochemical characterization of monoclonal antibodies against red cell markers related to expression of Lutheran blood group antigens. 
  • Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. 
  • Severe combined immunodeficiency with natural killer-cell predominance: abrogation of graft-versus-host disease and immunologic reconstitution with HLA-identical bone marrow cells. 
  • Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. 
  • Shift in S-layer protein expression responsible for antigenic variation in Campylobacter fetus. 
  • Sialic acid prevents loss of large von Willebrand factor multimers by protecting against amino-terminal proteolytic cleavage. 
  • Sialyl-dimeric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal cancer metastases. 
  • Side-chain specificities and molecular modelling of peptide determinants for two anti-Sm B/B' autoantibodies. 
  • Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque. 
  • Simultaneous capture and sequential detection of two malarial biomarkers on magnetic microparticles. 
  • Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. 
  • SnapShot: SARS-CoV-2 antibodies. 
  • Spatial profiles of hsp70 proteins in Asian clam (Potamocorbula amurensis) in northern San Francisco Bay may be linked to natural rather than anthropogenic stressors. 
  • Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums. 
  • Specific imaging of human brain tumor xenografts utilizing radiolabelled monoclonal antibodies (MAbs). 
  • Specific inhibition of tissue kallikrein 1 with a human monoclonal antibody reveals a potential role in airway diseases. 
  • Specificity analysis of monoclonal anti-DNA antibodies from B6-lpr/lpr mice. 
  • Specificity analysis of monoclonal anti-DNA antibodies. 
  • Specificity and idiotype analysis of a monoclonal anti-DNA antibody. 
  • Specificity and idiotypic analysis of a monoclonal anti-Sm antibody with anti-DNA activity. 
  • Specificity of anti-DNA antibodies induced in normal mice by immunization with bacterial DNA. 
  • Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. 
  • Split tolerance induced by immunotoxin in a rhesus kidney allograft model. 
  • Spondyloarthritis in a patient with unilateral buttock pain and history of Crohn disease. 
  • Spontaneous formation of germinal centers in autoimmune mice. 
  • Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions. 
  • Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. 
  • Staging non-small cell carcinoma of the lung using technetium-99m-labeled monoclonal antibodies. 
  • Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. 
  • Starting with the ABCs: Akt in breast cancer. 
  • Statin expression in the untreated and SarCNU-exposed human glioma cell line, SK-MG-1. 
  • Statin immunolocalization in human brain tumors. Detection of noncycling cells using a novel marker of cell quiescence. 
  • Stem cell transplantation for multiple myeloma. 
  • Stimulation of Acanthamoeba actomyosin ATPase activity by myosin-II polymerization. 
  • Stimulation of the T3-T cell receptor complex induces a membrane-potential-sensitive calcium influx. 
  • Stimulation of the T3-T cell receptor-associated Ca2+ influx enhances the activity of the Na+/H+ exchanger in a leukemic human T cell line. 
  • Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. 
  • Storage and mobilization of extracellular matrix proteins during sea urchin development. 
  • Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Strength through Organization: Classifying Antibody Activity against EBOV. 
  • Stromal gene signatures in large-B-cell lymphomas. 
  • Structural and functional studies of cyclic GMP phosphodiesterase. 
  • Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. 
  • Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. 
  • Structural features of nephritogenic lupus autoantibodies. 
  • Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. 
  • Structural properties of a subset of nephritogenic anti-DNA antibodies. 
  • Structurally Mapping Antigenic Epitopes of Adeno-associated Virus 9: Development of Antibody Escape Variants. 
  • Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s. 
  • Structure and function of anti-DNA autoantibodies derived from a single autoimmune mouse. 
  • Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. 
  • Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein. 
  • Subcutaneous efalizumab is not effective in the treatment of alopecia areata. 
  • Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. 
  • Successful conversion from conventional immunosuppression to anti-CD154 monoclonal antibody costimulatory molecule blockade in rhesus renal allograft recipients. 
  • Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab). 
  • Successful tumour immunotherapy: possible role of antibodies to anti-inflammatory factors produced by neoplasms. 
  • Superior in-hospital and 30-day outcomes with abciximab versus eptifibatide: a contemporary analysis of 495 consecutive percutaneous coronary interventions. 
  • Suppression of adaptive immune responses during primary SIV infection of sabaeus African green monkeys delays partial containment of viremia but does not induce disease. 
  • Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines. 
  • Suppression of human corneal epithelial proliferation with breast carcinoma immunotoxin. 
  • Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. 
  • Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. 
  • Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. 
  • Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. 
  • Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. 
  • Syn-capping of human T lymphocyte adhesion/activation molecules and their redistribution during interaction with endothelial cells. 
  • Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease. 
  • Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. 
  • Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents. 
  • Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses. 
  • Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. 
  • Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. 
  • Systemic lupus erythematosus. 
  • Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). 
  • T cell CD7 mRNA expression is regulated by both transcriptional and post-transcriptional mechanisms. 
  • T cell receptor gamma/delta expression on lymphocyte populations of breast cancer patients. 
  • T cell subpopulations in CLL: methods of T cell enrichment artificially alter proportions of OKT4 and OKT8 positive cells. 
  • T cells and T-cell subsets in a large population of patients with primary immunodeficiency. 
  • T lymphocyte depletion of human peripheral blood and bone marrow using monoclonal antibodies and magnetic microspheres. 
  • T-cell receptor-δ expression and γδ+ T-cell infiltrates in primary cutaneous γδ T-cell lymphoma and other cutaneous T-cell lymphoproliferative disorders. 
  • T-cell receptors of human suppressor cells. 
  • T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. 
  • T3 glycoprotein is functional although structurally distinct on human T-cell receptor gamma T lymphocytes. 
  • TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. 
  • TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. 
  • TNF is required for the induction but not the maintenance of compression-induced BME signals in murine tail vertebrae: limitations of anti-TNF therapy for degenerative disc disease. 
  • TNFalpha and IL-4 regulation of hyaluronan binding to monocyte CD44 involves posttranslational modification of CD44. 
  • Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. 
  • Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation. 
  • Targeted inhibition of VEGF receptor 2: an update on ramucirumab. 
  • Targeted radiotherapy of brain tumours. 
  • Targeted therapies for cancer 2004. 
  • Targeted therapy in rectal cancer. 
  • Targeted therapy of colorectal cancer: clinical experience with bevacizumab. 
  • Targeted therapy using alpha emitters. 
  • Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. 
  • Targeting CXCR4-dependent immunosuppressive Ly6C^low monocytes improves antiangiogenic therapy in colorectal cancer. 
  • Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy. 
  • Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. 
  • Targeting cell surface F1F0 ATP synthase in cancer therapy. 
  • Targeting the future in head and neck cancer. 
  • Targeting the programmed death-1 pathway in lymphoid neoplasms. 
  • Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. 
  • Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. 
  • Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. 
  • Tenascin-C knockout mouse has no detectable tenascin-C protein. 
  • Tenascin/hexabrachion in human skin: biochemical identification and localization by light and electron microscopy. 
  • Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. 
  • Terminin (Tp 63/60), a novel cell senescence-related protein, is present in the aging human hippocampus. 
  • The 40-kilodalton allergen of Candida albicans is an alcohol dehydrogenase: molecular cloning and immunological analysis using monoclonal antibodies. 
  • The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. 
  • The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen. 
  • The BB diabetic rat. Profound T-cell lymphocytopenia. 
  • The Binding of Monoclonal and Polyclonal Anti-Z-DNA Antibodies to DNA of Various Species Origin. 
  • The DEXH protein product of the DHX36 gene is the major source of tetramolecular quadruplex G4-DNA resolving activity in HeLa cell lysates. 
  • The EPILOG trial. Abciximab prevents ischemic complications during angioplasty. Evaluation in PTCA to improve Long-Term Outcome with Abciximab GP IIb/IIIa Blockade. 
  • The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis. 
  • The HB-6, CDw75, and CD76 differentiation antigens are unique cell-surface carbohydrate determinants generated by the beta-galactoside alpha 2,6-sialyltransferase. 
  • The IL-2 receptor gamma c chain does not function as a subunit shared by the IL-4 and IL-13 receptors. Implication for the structure of the IL-4 receptor. 
  • The PIG-A mutation and absence of glycosylphosphatidylinositol-linked proteins do not confer resistance to apoptosis in paroxysmal nocturnal hemoglobinuria. 
  • The Safety of available immunotherapy for the treatment of glioblastoma. 
  • The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma. 
  • The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. 
  • The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). 
  • The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. 
  • The application of monoclonal antibodies in the cytologic evaluation of tumors. 
  • The benefit of abciximab in percutaneous coronary revascularization is not device-specific. 
  • The biology of malignant gliomas--a comprehensive survey. 
  • The c-kit proto-oncogene receptor is expressed on a subset of human CD3-CD4-CD8- (triple-negative) thymocytes. 
  • The calm after the cytokine storm: lessons from the TGN1412 trial. 
  • The challenges of checkpoint inhibition in the treatment of multiple myeloma. 
  • The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. 
  • The clearance of a monoclonal anti-DNA antibody following administration of DNA in normal and autoimmune mice. 
  • The clinical application of monoclonal antibody therapies in renal transplantation. 
  • The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. 
  • The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. 
  • The common gamma-chain of cytokine receptors regulates intrathymic T cell development at multiple stages. 
  • The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention. 
  • The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. 
  • The cutaneous lymphocyte antigen is an essential component of the L-selectin ligand induced on human vascular endothelial cells. 
  • The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. 
  • The development of CD4 binding site antibodies during HIV-1 infection. 
  • The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). 
  • The dichotomous role of epiregulin in pain. 
  • The disappearance of a cyclin-like protein and the appearance of statin is correlated with the onset of differentiation during myogenesis in vitro. 
  • The distribution of intimal white blood cells in the normal rabbit aorta. 
  • The economics of PCSK-9 inhibitors. 
  • The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. 
  • The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. 
  • The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. 
  • The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells. 
  • The effects of clinically relevant hyperthermic temperatures on the kinetic binding parameters of a monoclonal antibody. 
  • The effects of local hyperthermia on the catabolism of a radioiodinated chimeric monoclonal antibody. 
  • The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. 
  • The efficacy of anti-PD-1 agents in acral and mucosal melanoma. 
  • The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow. 
  • The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. 
  • The expression of HMGB1 on microparticles from Jurkat and HL-60 cells undergoing apoptosis in vitro. 
  • The expression of plasma nucleosomes in mice undergoing in vivo apoptosis. 
  • The extent of amino-terminal heterogeneity in rabbit fast skeletal muscle troponin T. 
  • The fine specificity of monoclonal anti-DNA antibodies induced in normal mice by immunization with bacterial DNA. 
  • The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cells. 
  • The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population. 
  • The human genes for S-adenosylhomocysteine hydrolase and adenosine deaminase are syntenic on chromosome 20. 
  • The human thymic microenvironment during organ culture. 
  • The human thymic microenvironment. 
  • The human thymic microenvironment. Phenotypic characterization of Hassall's bodies with the use of monoclonal antibodies. 
  • The human thymic microenvironment: cortical thymic epithelium is an antigenically distinct region of the thymic microenvironment. 
  • The human thymic microenvironment: thymic epithelium contains specific keratins associated with early and late stages of epidermal keratinocyte maturation. 
  • The immunohistochemical application of three anti-GFAP monoclonal antibodies to formalin-fixed, paraffin-embedded, normal and neoplastic brain tissues. 
  • The immunohistochemical profile of the myelomeningocele placode: is the placode normal? 
  • The immunologic approach to analysis of malignant lymphoma. Mantle zone lymphoma of the ileocecal region. 
  • The impact of sharing results of a randomized breast cancer clinical trial with study participants. 
  • The in vivo antiviral effect of CL246,738 is mediated by the independent induction of interferon-alpha and interferon-beta. 
  • The inflammatory response to cardiopulmonary bypass. 
  • The influence of variable-region somatic mutations on the specificity and pathogenicity of murine monoclonal anti-DNA antibodies. 
  • The inhibition of anti-DNA binding to DNA by nucleic acid binding polymers. 
  • The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. 
  • The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice. 
  • The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. 
  • The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. 
  • The potential of monoclonal antibodies as carriers of radiation and drugs for immunodetection and therapy of brain tumors. 
  • The potential of monoclonal antibodies to reduce reperfusion injury in myocardial infarction. 
  • The production and characterization of murine monoclonal antibodies to human Gadd45 raised against a recombinant protein. 
  • The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials. 
  • The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. 
  • The risk and opportunity of homeostatic repopulation. 
  • The road to tolerance: renal transplant tolerance induction in nonhuman primate studies and clinical trials. 
  • The role of CD4-Lck in T-cell receptor antagonism: evidence for negative signaling. 
  • The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. 
  • The role of adhesion molecules in human leukocyte attachment to porcine vascular endothelium: implications for xenotransplantation. 
  • The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation. 
  • The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. 
  • The role of antigen specificity in the binding of murine monoclonal anti-DNA antibodies to microparticles from apoptotic cells. 
  • The role of glycoprotein IIb/IIIa platelet inhibition in percutaneous coronary intervention in the stent era. 
  • The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy. 
  • The role of leukocyte adhesion molecules in cellular interactions: implications for the pathogenesis of inflammatory synovitis. 
  • The role of receptors for complement in the induction of polyclonal B-cell proliferation and differentiation. 
  • The role of targeted therapy in the treatment of colorectal cancer. 
  • The role of the L3T4 molecule in mitogen and antigen-activated signal transduction. 
  • The role of the porcine von Willebrand factor: baboon platelet interactions in pulmonary xenotransplantation. 
  • The role of the specificity-determining loop of the integrin beta subunit I-like domain in autonomous expression, association with the alpha subunit, and ligand binding. 
  • The role of tumor markers in gynecologic oncology. 
  • The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes. 
  • The treatment of colorectal carcinoma: standard chemotherapy and beyond. 
  • The use of a panel of monoclonal antibodies in the evaluation of cytologic specimens from the central nervous system. 
  • The use of a panel of monoclonal antibodies in ultrastructurally characterized small cell carcinomas of the lung. 
  • The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. 
  • Therapeutic CD154 antibody for lupus: promise for the future? 
  • Therapeutic advancements in juvenile idiopathic arthritis. 
  • Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model. 
  • Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. 
  • Therapy and clinical trials. 
  • Three cell recognition changes accompany the ingression of sea urchin primary mesenchyme cells. 
  • Thromboelastography detects inadequate response to abciximab therapy during stent-assisted cerebral aneurysm coil embolization complicated by stroke. 
  • Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. 
  • Thymocyte LFA-1 and thymic epithelial cell ICAM-1 molecules mediate binding of activated human thymocytes to thymic epithelial cells. 
  • Thymocyte binding to human thymic epithelial cells is inhibited by monoclonal antibodies to CD-2 and LFA-3 antigens. 
  • Thymoma: lymphoid and epithelial components mirror the phenotype of normal thymus. 
  • Tides of inflammation: impact of biologics. 
  • Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction: the ASSENT-2 troponin substudy. 
  • Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. 
  • Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). 
  • Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. 
  • Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development. 
  • Tissue-specific migration pathways by phenotypically distinct subpopulations of memory T cells. 
  • Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. 
  • Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors. 
  • Topical bevacizumab therapy for corneal neovascularization. 
  • Topology of an amiloride-binding protein. 
  • Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes. 
  • Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. 
  • Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection. 
  • Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. 
  • Transplantation tolerance: a look at the nonhuman primate literature in the light of modern tolerance theories. 
  • Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. 
  • Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. 
  • Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. 
  • Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? 
  • Treatment Strategies for Deficiency of Adenosine Deaminase 2. 
  • Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab. 
  • Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. 
  • Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. 
  • Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6. 
  • Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. 
  • Treatment of newly diagnosed glioblastoma multiforme. 
  • Treatment of refractory acute rejection in a lung transplant recipient with campath 1H. 
  • Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. 
  • Treatment options for newly diagnosed patients with chronic lymphocytic leukemia. 
  • Treatment options in renal cell carcinoma: past, present and future. 
  • Treatment with a laminin-derived peptide suppresses lupus nephritis. 
  • Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. 
  • Treatment with immunotoxin. 
  • Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates. 
  • Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. 
  • Triiodothyronine stimulates cartilage growth and maturation by different mechanisms. 
  • Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. 
  • Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. 
  • Tumor antigens in astrocytic gliomas. 
  • Tumor necrosis factor blockers in rheumatoid arthritis. 
  • Tumor necrosis factor α antagonism improves neurological recovery in murine intracerebral hemorrhage. 
  • Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease. 
  • Tumor recognition and lytic competence of IL-2-activated lymphocytes: regulation of both antibody-independent and -dependent cellular cytotoxicity via P75 IL-2 receptor. 
  • Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. 
  • Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. 
  • Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis. 
  • Two Golgi integral membrane proteins (GIMPS) exhibit region- and cell type-specific distribution in the epididymis of the adult rat. 
  • Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. 
  • Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. 
  • Two embryonic, tissue-specific molecules identified by a double-label immunofluorescence technique for monoclonal antibodies. 
  • Tyrosine-sulfate isosteres of CCR5 N-terminus as tools for studying HIV-1 entry. 
  • Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. 
  • Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy. 
  • Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. 
  • Ultrastructural and biochemical properties of the 120-kDa form of chick kinectin. 
  • Ultraviolet light exposure suppresses contact hypersensitivity by abrogating endothelial intercellular adhesion molecule-1 up-regulation at the elicitation site. 
  • Unaltered graft survival and intragraft lymphocytes infiltration in the cardiac allograft of Cxcr3-/- mouse recipients. 
  • Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. 
  • Uncommon structural motifs dominate the antigen binding site in human autoantibodies reactive with basement membrane collagen. 
  • Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration. 
  • Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. 
  • Unfractionated heparin reduces the anti-platelet effects of abciximab but not eptifibatide during PCI. 
  • Unique proteins defined by monoclonal antibodies specific for human melanoma. Some potential clinical applications. 
  • Unsticking platelets: the role of glycoprotein IIb/IIIa receptor blockade. 
  • Unusual clinical and immunologic manifestations of transplacentally acquired maternal T cells in severe combined immunodeficiency. 
  • Update on treatment advances in combined-modality therapy for anal and rectal carcinomas. 
  • Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. 
  • Updates on Merkel Cell Carcinoma. 
  • Upregulation of molecules associated with T-regulatory function by thymoglobulin pretreatment of human CD4+ cells. 
  • Uptake of KRAS Testing and Anti-EGFR Antibody Use for Colorectal Cancer in the VA. 
  • Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland. 
  • Use of OKT3 in kidney, pancreas, and liver transplantation. 
  • Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. 
  • Use of anti-idiotypic antibodies to establish that monoclonal antibody 7H11D6 binds to the alpha 2-macroglobulin receptor recognition site. 
  • Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction. 
  • Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. 
  • Use of heterohybridomas in xenotransplantation. 
  • Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells. 
  • Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer. 
  • Use of monoclonal antibodies to probe subunit- and polymer-specific epitopes of 987P fimbriae of Escherichia coli. 
  • Use of radiolabeled monoclonal anti-B1 antibody for B lymphocyte imaging in rhesus monkeys. 
  • Use of trastuzumab in the treatment of metastatic endometrial cancer. 
  • Use of tumor necrosis factor inhibitors in uveitis. 
  • Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors. 
  • Usefulness of the QRS score as a strong prognostic marker in patients discharged after undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. 
  • Using microcantilever deflection to detect HIV-1 envelope glycoprotein gp120. 
  • Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. 
  • Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy. 
  • V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. 
  • V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network. 
  • VEGF inhibition and renal thrombotic microangiopathy. 
  • Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. 
  • Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. 
  • Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. 
  • Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide. 
  • Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. 
  • Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. 
  • Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. 
  • Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. 
  • Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. 
  • Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. 
  • Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. 
  • Viral infection abrogates CD8(+) T-cell deletion induced by costimulation blockade. 
  • Visualization of P-selectin glycoprotein ligand-1 as a highly extended molecule and mapping of protein epitopes for monoclonal antibodies. 
  • Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. 
  • Workshop on monoclonal antibodies against gliomas and other neuroectoderm-derived tumors. 
  • Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons? 
  • YJ5 as an immunohistochemical marker of osteogenic lineage. 
  • ZIKV-Specific NS1 Epitopes as Serological Markers of Acute Zika Virus Infection. 
  • Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. 
  • [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. 
  • [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. 
  • [Intraportal injection of specific monoclonal antibody in nude mice with liver metastasis]. 
  • [Significance of monoclonal antibodies in diagnosis and therapy of tumors of the central nervous system]. 
  • [Studies on human porin. V. The expression of "porin31HL" in the plasmalemma is not by cell transformation]. 
  • d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution. 
  • mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. 
  • miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy. 
  • p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. 
  • p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Allen, Nancy Bates, Professor Emeritus of Medicine, Medicine, Rheumatology and Immunology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Buckley, Anne Frances, Assistant Professor of Pathology, Pathology
  • Erickson, Harold Paul, James B. Duke Distinguished Professor Emeritus, Cell Biology
  • Esclamado, Ramon Mitra, Richard Hall Chaney, Sr. Distinguished Professor Emeritus of Otolaryngology, Head and Neck Surgery & Communication Sciences
  • Ferrari, Guido, Professor in Surgery, Molecular Genetics and Microbiology
  • Gunn, Michael Dee, Professor of Medicine, Integrative Immunobiology
  • Hogan, Brigid L. M., Research Professor of Cell Biology, Cell Biology
  • James, Michael Lucas, Associate Professor of Anesthesiology, Anesthesiology
  • Kelsoe, Garnett H., James B. Duke Distinguished Professor of Immunology, Integrative Immunobiology
  • Krangel, Michael S., George Barth Geller Distinguished Professor of Immunology, Integrative Immunobiology
  • Lagoo, Anand Shreeram, Professor of Pathology, Pathology
  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Science & Society
  • Luftig, Micah Alan, Professor of Molecular Genetics and Microbiology, Cell Biology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Mruthyunjaya, Prithvi, Adjunct Associate Professor in the Department of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Schanberg, Laura Eve, Professor of Pediatrics, Pediatrics, Rheumatology
  • Sunday, Mary Elizabeth Anne, Professor of Pathology, Cell Biology
  • Taylor, Gregory Alan, Professor in Medicine, Integrative Immunobiology
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Integrative Immunobiology
  • Zafar, Syed Yousuf, Adjunct Professor in the Department of Medicine, Duke Science & Society